1. Dubos R. Mirage of Health: Utopias, Progress, and Biological Change. New York: Harper & Brothers; 1959.
2. Dorsey ER, Bloem BR. The Parkinson pandemic—a call to action. JAMA Neurology. 2018;75(1):9–10.
3. GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurology. 2017;16(11):877–897.
4. Dorsey ER, Bloem BR. The Parkinson pandemic—a call to action. JAMA Neurology. 2018;75(1):9–10.
5. Ibid.
6. Ascherio A, Schwarzschild MA. The epidemiology of Parkinson’s disease: risk factors and prevention. Lancet Neurology. 2016;15(12):1257–1272; Goldman SM. Environmental toxins and Parkinson’s disease. Annual Review of Pharmacology and Toxicology. 2014;54(1):141–164; Elbaz A, Carcaillon L, Kab S, Moisan F. Epidemiology of Parkinson’s disease. Revue Neurologique. 2016;172(1):14–26.
7. Shulman LM, Katzel LI, Ivey FM, et al. Randomized clinical trial of 3 types of physical exercise for patients with Parkinson disease. JAMA Neurology. 2013;70(2):183–190; Rosenthal LS, Dorsey ER. The benefits of exercise in Parkinson disease. JAMA Neurology. 2013;70(2):156–157; Li F, Harmer P, Fitzgerald K, et al. Tai chi and postural stability in patients with Parkinson’s disease. New England Journal of Medicine. 2012;366(6):511–519.
8. Goldman SM. Environmental toxins and Parkinson’s disease. Annual Review of Pharmacology and Toxicology. 2014;54(1):141–164; Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. New England Journal of Medicine. 2006;355(9):896–908.
9. Factor SA, Feustel PJ, Friedman JH, et al. Longitudinal outcome of Parkinson’s disease patients with psychosis. Neurology. 2003;60(11):1756–1761; Parashos SA, Maraganore DM, O’Brien PC, Rocca WA. Medical services utilization and prognosis in Parkinson disease: a population-based study. Mayo Clinic Proceedings. 2002;77(9):918–925; Schrag A, Hovris A, Morley D, Quinn N, Jahanshahi M. Caregiver-burden in Parkinson’s disease is closely associated with psychiatric symptoms, falls, and disability. Parkinsonism & Related Disorders. 2006;12(1):35–41; Aarsland D, Larsen JP, Karlsen K, Lim NG, Tandberg E. Mental symptoms in Parkinson’s disease are important contributors to caregiver distress. International Journal of Geriatric Psychiatry. 1999;14(10):866–874.
10. Buter TC, van den Hout A, Matthews FE, Larsen JP, Brayne C, Aarsland D. Dementia and survival in Parkinson disease: a 12-year population study. Neurology. 2008;70(13):1017–1022; Beyer MK, Herlofson K, Aarsland D, Larsen JP. Causes of death in a community-based study of Parkinson’s disease. Acta Neurologica Scandinavica. 2001;103(1):7–11; Fall PA, Saleh A, Fredrickson M, Olsson J-E, Granérus A-K. Survival time, mortality, and cause of death in elderly patients with Parkinson’s disease: a 9-year follow-up. Movement Disorders. 2003;18(11):1312–1316.
11. Parkinson J. An essay on the shaking palsy. Journal of Neuropsychiatry and Clinical Neurosciences. 2002;14(2):223–236.
12. The 20th century mortality files, 1901–2000. Office for National Statistics. March 11, 2011. https://webarchive.nationalarchives.gov.uk/20150908090558; www.ons.gov.uk/ons/publications/re-reference-tables.html?edition=tcm%3A77-215593. Accessed January 22, 2019; Duvoisin RC, Schweitzer MD. Paralysis agitans mortality in England and Wales, 1855–1962. British Journal of Preventive and Social Medicine. 1966;20(1):27–33.
13. More C. Understanding the Industrial Revolution. 1st ed. Routledge; 2000.
14. Ritchie H. What the history of London’s air pollution can tell us about the future of today’s growing megacities. Our World in Data. June 20, 2017. https://ourworldindata.org/london-air-pollution. Accessed December 12, 2018; Roser M, Ritchie H. Fertilizer and pesticides. Our World in Data. 2019. https://ourworldindata.org/fertilizer-and-pesticides. Accessed March 25, 2019; Manganese: history and industry development. Metalpedia. http://metalpedia.asianmetal.com/metal/manganese/history.shtml. Accessed March 28, 2019; Bell T. The history of steel: From Iron Age to electric arc furnaces. The Balance. www.thebalance.com/steel-history-2340172. Updated June 25, 2019. Accessed March 28, 2019; Caudle WM, Guillot TS, Lazo CR, Miller GW. Industrial toxicants and Parkinson’s disease. Neurotoxicology. 2012;33(2):178–188.
15. Roser M, Ritchie H. Fertilizer and pesticides. Our World in Data. https://ourworldindata.org/fertilizer-and-pesticides. Accessed March 25, 2019.
16. Ascherio A, Chen H, Weisskopf MG, et al. Pesticide exposure and risk for Parkinson’s disease. Annals of Neurology. 2006;60(2):197–203; Semchuk KM, Love EJ, Lee RG. Parkinson’s disease and exposure to agricultural work and pesticide chemicals. Neurology. 1992;42(7):1328–1328; Pezzoli G, Cereda E. Exposure to pesticides or solvents and risk of Parkinson disease. Neurology. 2013;80(22):2035–2041; Tanner CM, Kamel F, Ross GW, et al. Rotenone, paraquat, and Parkinson’s disease. Environmental Health Perspectives. 2011;119(6):866–872.
17. Caudle WM, Guillot TS, Lazo CR, Miller GW. Industrial toxicants and Parkinson’s disease. Neurotoxicology. 2012;33(2):178–188; Betarbet R, Sherer TB, Greenamyre JT. Animal models of Parkinson’s disease. BioEssays. 2002;24(4):308–318; Uversky VN. Neurotoxicant-induced animal models of Parkinson’s disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell and Tissue Research. 2004;318(1):225–241.
18. Hogue C. Trump administration delays bans of toxic solvents. Chemical & Engineering News. December 20, 2017. https://cen.acs.org/articles/95/web/2017/12/Trump-administration-delays-bans-toxic.html. Accessed March 28, 2019.
19. Barringer F. E.P.A. charts risks of a ubiquitous chemical. New York Times. September 30, 2011; Vettel P. Worried about decaf coffee? Fears are groundless. Chicago Tribune. May 19, 1985. www.chicagotribune.com/news/ct-xpm-1985-05-19-8502010068-story.html. Accessed July 19, 2019.
20. What is Superfund? US Environmental Protection Agency. www.epa.gov/superfund/what-superfund. Updated November 30, 2018. Accessed March 28, 2019.
21. Record of decision: Modock Road Springs/DLS Sand and Gravel, Inc. Site, Town of Victor, Ontario County, New York, Site Number 8-35-013. New York State Department of Environmental Conservation. January 2010. www.dec.ny.gov/docs/remediation_hudson_pdf/835013rod.pdf. Accessed March 29, 2019.
22. Trichloroethylene. US Environmental Protection Agency. April 1992. www.epa.gov/sites/production/files/2016-09/documents/trichloroethylene.pdf. Updated January 2000. Accessed March 28, 2019.
23. Trichloroethylene (TCE) general fact sheet. In Agency for Toxic Substances and Disease Registry, US Department of Health and Human Services. www.gsa.gov/cdnstatic/Trichloroethylene_%28TCE%29_NEW_general_fact_sheet.pdf. Accessed March 29, 2019.
24. Risk management for trichloroethylene (TCE). US Environmental Protection Agency. www.epa.gov/assessing-and-managing-chemicals-under-tsca/risk-management-trichloroethylene-tce. Updated December 14, 2017. Accessed November 16, 2018; Integrated Risk Information System: trichloroethylene. US Environmental Protection Agency. https://cfpub.epa.gov/ncea/iris2/chemicalLanding.cfm?substance_nmbr=199. Updated July 28, 2017. Accessed March 28, 2019.
25. Watts M. Paraquat. Pesticide Action Network Asia & the Pacific. February 2011. www.panna.org/sites/default/files/Paraquat%20monograph%20final%202011-1.pdf. Accessed June 28, 2019; China about to ban all sales and use of paraquat by 2020 [press release]. CCM Data & Business Intelligence, July 31, 2017. www.cnchemicals.com/Press/89866-China%20about%20to%20ban%20all%20sales%20and%20use%20of%20paraquat%20by%202020.html. Accessed June 28, 2019.
26. Tanner CM, Kamel F, Ross GW, et al. Rotenone, paraquat, and Parkinson’s disease. Environmental Health Perspectives. 2011;119(6):866–872.
27. Pesticide National Synthesis Project: estimated annual agricultural pesticide use. US Geological Survey. https://water.usgs.gov/nawqa/pnsp/usage/maps/show_map.php?year=2015&map=PARAQUAT&hilo=H. Updated September 11, 2018. Accessed March 25, 2019.
28. Jenkins D. Court grants EPA new hearing on pesticide ban. Capital Press. February 12, 2019; O’Neill E. Will an appeals court make the EPA ban a pesticide linked to serious health risks? The Salt. February 26, 2019. www.npr.org/sections/thesalt/2019/02/26/698227414/will-an-appeals-court-make-the-epa-ban-a-pesticide-linked-to-serious-health-risk. Accessed June 28, 2019.
29. Friedman L. E.P.A. won’t ban chlorpyrifos, pesticide tied to children’s health problems. New York Times. July 18, 2019. www.nytimes.com/2019/07/18/climate/epa-chlorpyrifos-pesticide-ban.html?smid=nytcore-ios-share.
30. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. American Journal of Human Genetics. 1998;62(3):676–689; Danaei G, Vander Hoorn S, Lopez AD, Murray CJL, Ezzati M. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. The Lancet. 2005;366(9499):1784–1793; Brody JG, Moysich KB, Humblet O, Attfield KR, Beehler GP, Rudel RA. Environmental pollutants and breast cancer. Cancer. 2007;109(S12):2667–2711; McPherson K, Steel CM, Dixon JM. ABC of breast diseases. Breast cancer—epidemiology, risk factors, and genetics. BMJ. 2000;321(7261):624–628.
31. Hofman A, Stricker BH, Ikram MA, Koudstaal PJ, Darweesh SKL. Trends in the incidence of Parkinson disease in the general population: the Rotterdam Study. American Journal of Epidemiology. 2016;183(11):1018–1026.
32. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nature Neuroscience. 2000;3(12):1301–1306.
33. Okun MS. Parkinson’s Treatment: 10 Secrets to a Happier Life. CreateSpace; 2013; Okun MS, Gallo BV, Mandybur G, et al. Subthalamic deep brain stimulation with a constant-current device in Parkinson’s disease: an open-label randomised controlled trial. Lancet Neurology. 2012;11(2):140–149; Okun MS, Fernandez HH, Wu SS, et al. Cognition and mood in Parkinson’s disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE Trial. Annals of Neurology. 2009;65(5):586–595; Okun MS. Ask the Doctor About Parkinson’s Disease. 1st ed. Demos Health; 2009. Okun MS. 10 Breakthrough Therapies for Parkinson’s Disease: English Edition. 1st ed. Books4Patients; 2015.
34. Bloem BR, Hausdorff JM, Visser JE, Giladi N. Falls and freezing of gait in Parkinson’s disease: a review of two interconnected, episodic phenomena. Movement Disorders. 2004;19(8):871–884; Bloem BR, Grimbergen YAM, Cramer M, Willemsen M, Zwinderman AH. Prospective assessment of falls in Parkinson’s disease. Journal of Neurology. 2001;248(11):950–958; Nijkrake MJ, Keus SHJ, Overeem S, et al. The ParkinsonNet concept: development, implementation and initial experience. Movement Disorders. 2010;25(7):823–829; Bloem BR, Rompen L, de Vries NM, Klink A, Munneke M, Jeurissen P. ParkinsonNet: a low-cost health care innovation with a systems approach from the Netherlands. Health Affairs. 2017;36:1987–1996.
35. Beck CA, Beran DB, Biglan KM, et al. National randomized controlled trial of virtual house calls for Parkinson disease. Neurology. 2017;89(11):1152–1161; Dorsey ER, Venkataraman V, Grana MJ, et al. Randomized controlled clinical trial of “virtual house calls” for Parkinson disease. JAMA Neurology. 2013;70(5):565–570.
1. Parkinson J. An essay on the shaking palsy. Journal of Neuropsychiatry and Clinical Neurosciences. 2002;14(2):223–236.
2. Morris AD, Rose FC. James Parkinson: His Life and Times. Boston: Birkhauser; 1989.
3. Blake, W. The Poetical Works of William Blake, ed. by John Sampson. London, New York: Oxford University Press, 1908; Bartleby.com, 2011. www.bartleby.com/235/284.html.
4. Ritchie H. What the history of London’s air pollution can tell us about the future of today’s growing megacities. Our World in Data. June 20, 2017. https://ourworldindata.org/london-air-pollution. Accessed December 12, 2018.
5. Ibid.
6. Morris AD, Rose FC. James Parkinson: His Life and Times. Birkhauser; 1989.
7. Ibid.
8. Ibid.
9. Ibid.
10. Zhang Z, Dong Z, Román GC. Early descriptions of Parkinson disease in ancient China. Archives of Neurology. 2006;63(5):782–784; Ovallath S, Deepa P. The history of parkinsonism: descriptions in ancient Indian medical literature. Movement Disorders. 2013;28(5):566–568; Obeso JA, Stamelou M, Goetz CG, et al. Past, present, and future of Parkinson’s disease: a special essay on the 200th anniversary of the shaking palsy. Movement Disorders. 2017;32(9):1264–1310; Lees AJ. Unresolved issues relating to the shaking palsy on the celebration of James Parkinson’s 250th birthday. Movement Disorders. 2007;22(S17):S327–S334.
11. Zhang Z, Dong Z, Román GC. Early descriptions of Parkinson disease in ancient China. Archives of Neurology. 2006;63(5):782–784; Ovallath S, Deepa P. The history of parkinsonism: descriptions in ancient Indian medical literature. Movement Disorders. 2013;28(5):566–568.
12. Obeso JA, Stamelou M, Goetz CG, et al. Past, present, and future of Parkinson’s disease: a special essay on the 200th anniversary of the shaking palsy. Movement Disorders. 2017;32(9):1264–1310.
13. Goetz CG. The history of Parkinson’s disease: early clinical descriptions and neurological therapies. Cold Spring Harbor Perspectives in Medicine. 2011;1(1):a008862.
14. Obeso JA, Stamelou M, Goetz CG, et al. Past, present, and future of Parkinson’s disease: a special essay on the 200th anniversary of the shaking palsy. Movement Disorders. 2017;32(9):1264–1310; Goetz CG. The history of Parkinson’s disease: early clinical descriptions and neurological therapies. Cold Spring Harbor Perspectives in Medicine. 2011;1(1):a008862.
15. Osler W, Sir. The Principles and Practice of Medicine. New York: D. Appleton and Company; 1892.
16. Carlsson A. Nobel lecture: a half-century of neurotransmitter research: impact on neurology and psychiatry. Bioscience Reports. 2001;21(6):691–710.
17. Ibid.; Lees AJ, Tolosa E, Olanow CW. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr. Movement Disorders. 2015;30(1):19–36.
18. Lees AJ, Tolosa E, Olanow CW. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr. Movement Disorders. 2015;30(1):19–36.
19. Carlsson A. Nobel lecture: a half-century of neurotransmitter research: impact on neurology and psychiatry. Bioscience Reports. 2001;21(6):691–710.
20. Hagerty JR. Arvid Carlsson, snubbed at University in Sweden, found a path to Nobel Prize in medicine. Wall Street Journal. July 13, 2018.
21. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. Journal of the Neurological Sciences. 1973;20(4):415–455.
22. Lees AJ, Tolosa E, Olanow CW. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr. Movement Disorders. 2015;30(1):19–36.
23. Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson’s disease–related pathology. Cell and Tissue Research. 2004;318(1):121–134; Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rüb U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson’s disease (preclinical and clinical stages). Journal of Neurology. 2002;249(3):iii1–iii5.
24. Chaudhuri KR, Healy DG, Schapira AHV. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurology. 2006;5(3):235–245; Park A, Stacy M. Non-motor symptoms in Parkinson’s disease. Journal of Neurology. 2009;256(3):293–298.
25. Schrag A. Quality of life and depression in Parkinson’s disease. Journal of the Neurological Sciences. 2006;248(1):151–157; Shulman LM, Taback RL, Bean J, Weiner WJ. Comorbidity of the nonmotor symptoms of Parkinson’s disease. Movement Disorders. 2001;16(3):507–510; Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Movement Disorders. 2011;26(3):399–406.
26. Lees AJ, Tolosa E, Olanow CW. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr. Movement Disorders. 2015;30(1):19–36.
27. Goetz CG. The history of Parkinson’s disease: early clinical descriptions and neurological therapies. Cold Spring Harbor Perspectives in Medicine. 2011;1(1):a008862; Birkmayer W, Hornykiewicz O. The L-3,4-dioxyphenylalanine (DOPA)–effect in Parkinson-akinesia. Wiener klinische Wochenschrift. 1961;73:787–788.
28. Cotzias GC. L-dopa for Parkinsonism. New England Journal of Medicine. 1968;278(11):630; Cotzias GC, Papavasiliou PS, Gellene R. Modification of parkinsonism—chronic treatment with L-dopa. New England Journal of Medicine. 1969;280(7):337–345; Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM. Treatment of parkinsonism with levodopa. Archives of Neurology. 1969;21(4):343–354.
29. Sacks O. Awakenings. Rpt. ed. Vintage; 1999.
30. Parkinson J. An essay on the shaking palsy. Journal of Neuropsychiatry and Clinical Neurosciences. 2002;14(2):223–236.
31. Osler W, Sir. The Principles and Practice of Medicine. D. Appleton and Company; 1892.
32. Langston JW. The MPTP story. Journal of Parkinson’s Disease. 2017;7(s1):S11–S19.
33. Ibid.
34. Langston JW, Palfreman J. The Case of the Frozen Addicts: How the Solution of a Medical Mystery Revolutionized the Understanding of Parkinson’s Disease. Rev. ed. IOS Press; 2014.
35. Langston JW. The MPTP story. Journal of Parkinson’s Disease. 2017;7(s1):S11–S19; Nonnekes J, Post B, Tetrud JW, Langston JW, Bloem BR. MPTP-induced parkinsonism: an historical case series. Lancet Neurology. 2018;17(4):300–301.
36. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219(4587):979–980.
37. “NOVA; case of the frozen addict, the.” OpenVault from WGBH Boston/BBC TV. February 18, 1986. http://openvault.wgbh.org/catalog/V_474CF2C8A20B4173988486AC4C605A3C. At 00:55:25.
38. Cervone C. Frozen addicts; drug addicts developed Parkinson’s disease. Las Vegas World News. December 9, 2013. www.lasvegasworldnews.com/frozen-addicts-drug-addicts-developed-parkinsons-disease/14976. Accessed December 13, 2018.
39. Desmethylprodine. Wikipedia. https://en.wikipedia.org/wiki/Desmethylprodine. Updated December 31, 2018. Accessed March 31, 2019.
40. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. Journal of Neurology, Neurosurgery, and Psychiatry. 1992;55(3):181–184.
41. Davis GC, Williams AC, Markey SP, et al. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Research. 1979;1(3):249–254.
42. Ibid.
43. Designer drugs: hearing before the Committee on the Budget, United States Senate, Ninety-Ninth Congress, first session, July 18, 1985. US Government Publishing Office; 1985.
44. Ibid.
45. Sinclair M. Tragedy has designer label. Washington Post. July 19, 1985.
46. Ibid.
47. Langston JW, Palfreman J. The Case of the Frozen Addicts: How the Solution of a Medical Mystery Revolutionized the Understanding of Parkinson’s Disease. Rev. ed. IOS Press; 2014.
48. Davis GC, Williams AC, Markey SP, et al. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Research. 1979;1(3):249–254.
49. Ibid.
50. Langston JW, Palfreman J. The Case of the Frozen Addicts: How the Solution of a Medical Mystery Revolutionized the Understanding of Parkinson’s Disease. Rev. ed. IOS Press; 2014.
51. Designer drugs: hearing before the Committee on the Budget, United States Senate, Ninety-Ninth Congress, first session, July 18, 1985. US Government Publishing Office; 1985.
52. Sinclair M. Tragedy has designer label. Washington Post. July 19, 1985.
53. Davis GC, Williams AC, Markey SP, et al. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Research. 1979;1(3):249–254.
54. Designer drugs: hearing before the Committee on the Budget, United States Senate, Ninety-Ninth Congress, first session, July 18, 1985. US Government Publishing Office; 1985.
55. Langston JW. The MPTP story. Journal of Parkinson’s Disease. 2017;7(s1):S11–S19.
56. Ibid.
57. Goldman SM. Environmental toxins and Parkinson’s disease. Annual Review of Pharmacology and Toxicology. 2014;54(1):141–164; Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nature Neuroscience. 2000;3(12):1301–1306; Fleming L, Mann JB, Bean J, Briggle T, Sanchez-Ramos JR. Parkinson’s disease and brain levels of organochlorine pesticides. Annals of Neurology. 1994;36(1):100–103; Priyadarshi A, Khuder SA, Schaub EA, Shrivastava S. A meta-analysis of Parkinson’s disease and exposure to pesticides. Neurotoxicology. 2000;21(4):435–440.
58. Langston JW. The MPTP story. Journal of Parkinson’s Disease. 2017;7(s1):S11–S19.
59. “NOVA; case of the frozen addict, the.” OpenVault from WGBH Boston/BBC TV. February 18, 1986. http://openvault.wgbh.org/catalog/V_474CF2C8A20B4173988486AC4C605A3C. At 00:55:25.
60. Meredith GE, Rademacher DJ. MPTP mouse models of Parkinson’s disease: an update. Journal of Parkinson’s Disease. 2011;1(1):19–33; Porras G, Li Q, Bezard E. Modeling Parkinson’s disease in primates: the MPTP model. Cold Spring Harbor Perspectives in Medicine. 2012;2(3):a009308.
61. Cornelius CE. Animal models—a neglected medical resource. New England Journal of Medicine. 1969;281(17):934–944; Overall KL. Natural animal models of human psychiatric conditions: assessment of mechanism and validity. Progress in Neuro-psychopharmacology and Biological Psychiatry. 2000;24(5):727–776.
62. Barré-Sinoussi F, Montagutelli X. Animal models are essential to biological research: issues and perspectives. Future Science OA. 2015;1(4):FSO63–FSO63.
63. Ibid.
64. Giasson BI, Lee VMY. A new link between pesticides and Parkinson’s disease. Nature Neuroscience. 2000;3:1227–1228.
65. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nature Neuroscience. 2000;3(12):1301–1306.
66. Giasson BI, Lee VMY. A new link between pesticides and Parkinson’s disease. Nature Neuroscience. 2000;3:1227–1228.
67. Tanner CM, Kamel F, Ross GW, et al. Rotenone, paraquat, and Parkinson’s disease. Environmental Health Perspectives. 2011;119(6):866–872.
68. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the α-synuclein gene identified in families with Parkinson’s disease. Science. 1997;276(5321):2045–2047.
69. Olanow CW, Brundin P. Parkinson’s disease and alpha synuclein: is Parkinson’s disease a prion-like disorder? Movement Disorders. 2013;28(1):31–40; Uversky VN, Li J, Fink AL. Pesticides directly accelerate the rate of α-synuclein fibril formation: a possible factor in Parkinson’s disease. FEBS Letters. 2001;500(3):105–108.
70. Luk KC, Kehm V, Carroll J, et al. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012;338(6109):949–953.
71. Goedert M, Spillantini MG, Del Tredici K, Braak H. 100 years of Lewy pathology. Nature Reviews Neurology. 2013;9(1):13–24.
72. Spillantini MG, Schmidt ML, Lee VMY, Trojanowski JQ, Jakes R, Goedert M. α-synuclein in Lewy bodies. Nature. 1997;388:839–840; Mezey E, Dehejia AM, Harta G, et al. Alpha synuclein is present in Lewy bodies in sporadic Parkinson’s disease. Molecular Psychiatry. 1998;3:493–499.
73. Holdorff B. Friedrich Heinrich Lewy (1885–1950) and his work. Journal of the History of the Neurosciences. 2002;11(1):19–28.
74. Brin S. LRRK2. Too. September 18, 2008. http://too.blogspot.com/2008/09/lrrk2.html.
75. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44(4):601–607.
76. Ibid.; Gilks WP, Abou-Sleiman PM, Gandhi S, et al. A common LRRK2 mutation in idiopathic Parkinson’s disease. The Lancet. 2005;365(9457):415–416; Di Fonzo A, Rohé CF, Ferreira J, et al. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson’s disease. The Lancet. 2005;365(9457):412–415.
77. Brin S. LRRK2. Too. September 18, 2008. http://too.blogspot.com/2008/09/lrrk2.html.
78. Ibid.
79. Sergey Brin. Inside Philanthropy. www.insidephilanthropy.com/guide-to-individual-donors/sergey-brin.html. Accessed March 20, 2019; Goetz T. Sergey Brin’s search for a Parkinson’s cure. Wired. January 22, 2010. www.wired.com/2010/06/ff-sergeys-search. Accessed June 28, 2019.
80. The Associated Press. Twins study links Parkinson’s disease to the environment. New York Times. February 2, 1999.
81. Klein C, Westenberger A. Genetics of Parkinson’s disease. Cold Spring Harbor Perspectives in Medicine. 2012;2(1):a008888; Fleming SM. Mechanisms of gene-environment interactions in Parkinson’s disease. Current Environmental Health Reports. 2017;4(2):192–199.
82. Klein C, Westenberger A. Genetics of Parkinson’s disease. Cold Spring Harbor Perspectives in Medicine. 2012;2(1):a008888.
83. Fleming SM. Mechanisms of gene-environment interactions in Parkinson’s disease. Current Environmental Health Reports. 2017;4(2):192–199.
84. www.reuters.com/article/us-cancer-lung-nutrients-sb/nutrients-may-be-why-some-smokers-avoid-cancer-idUSTRE65E5JW20100616.
85. www.nature.com/articles/nature06846; www.nature.com/articles/ng.3892.
86. www.ncbi.nlm.nih.gov/pmc/articles/PMC4501942; https://pubmed.ncbi.nlm.nih.gov/28639421-penetrance-estimate-of-lrrk2-pg2019s-mutation-in-individuals-of-non-ashkenazi-jewish-ancestry.
87. Ryan SD, Dolatabadi N, Chan SF, et al. Isogenic human iPSC Parkinson’s model shows nitrosative stress-induced dysfunction in MEF2-PGC1α transcription. Cell. 2013;155(6):1351–1364.
88. Nuber S, Tadros D, Fields J, et al. Environmental neurotoxic challenge of conditional alpha-synuclein transgenic mice predicts a dopaminergic olfactory-striatal interplay in early PD. Acta Neuropathologica. 2014;127(4):477–494.
89. Liu H-F, Ho PW-L, Leung GC-T, et al. Combined LRRK2 mutation, aging and chronic low dose oral rotenone as a model of Parkinson’s disease. Scientific Reports. 2017;7:40887. doi:10.1038/srep40887.
90. Weiner WJ. There is no Parkinson disease. Archives of Neurology. 2008;65(6):705–708.
91. Malek N, Weil RS, Bresner C, et al. Features of GBA-associated Parkinson’s disease at presentation in the UK Tracking Parkinson’s study. Journal of Neurology, Neurosurgery & Psychiatry. 2018;89(7):702–709; Saunders-Pullman R, Mirelman A, Alcalay RN, et al. Progression in the LRRK2-associated Parkinson disease population. JAMA Neurology. 2018;75(3):312–319.
92. Parkinson J. An essay on the shaking palsy. Journal of Neuropsychiatry and Clinical Neurosciences. 2002;14(2):223–236.
93. Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiology of Aging. 2003;24(2):197–211; Braak H, Rüb U, Gai WP, Del Tredici K. Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. Journal of Neural Transmission. 2003;110(5):517–536.
94. Braak H, Rüb U, Gai WP, Del Tredici K. Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. Journal of Neural Transmission. 2003;110(5):517–536.
95. Silva BA, Einarsdóttir O, Fink AL, Uversky VN. Biophysical characterization of α-synuclein and rotenone interaction. Biomolecules. 2013;3(3):703–732.
96. Del Tredici K, Hawkes CH, Ghebremedhin E, Braak H. Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson’s disease. Acta Neuropathologica. 2010;119(6):703–713; Del Tredici K, Braak H. Spinal cord lesions in sporadic Parkinson’s disease. Acta Neuropathologica. 2012;124(5):643–664.
97. Breen DP, Halliday GM, Lang AE. Gut-brain axis and the spread of α-synuclein pathology: vagal highway or dead end? Movement Disorders. 2019;34(3):307–316.
98. Braak H, Rüb U, Gai WP, Del Tredici K. Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. Journal of Neural Transmission. 2003;110(5):517–536.
99. Pan-Montojo F, Anichtchik O, Dening Y, et al. Progression of Parkinson’s disease pathology is reproduced by intragastric administration of rotenone in mice. PLOS ONE. 2010;5(1):e8762; Holmqvist S, Chutna O, Bousset L, et al. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathologica. 2014;128(6):805–820.
100. Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiology of Aging. 2003;24(2):197–211.
101. Stokholm MG, Danielsen EH, Hamilton-Dutoit SJ, Borghammer P. Pathological α-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. Annals of Neurology. 2016;79(6):940–949; Ross GW, Abbott RD, Petrovitch H, et al. Association of olfactory dysfunction with incidental Lewy bodies. Movement Disorders. 2006;21(12):2062–2067.
102. Chaudhuri KR, Healy DG, Schapira AHV. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurology. 2006;5(3):235–245; Winge K, Skau A-M, Stimpel H, Nielsen KK, Werdelin L. Prevalence of bladder dysfunction in Parkinsons disease. Neurourology and Urodynamics. 2006;25(2):116–122; Aarsland D, Andersen K, Larsen JP, Lolk A. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Archives of Neurology. 2003;60(3):387–392; Hely MA, Reid WGJ, Adena MA, Halliday GM, Morris JGL. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Movement Disorders. 2008;23(6):837–844.
103. Svensson E, Horváth-Puhó E, Thomsen RW, et al. Vagotomy and subsequent risk of Parkinson’s disease. Annals of Neurology. 2015;78(4):522–529.
1. Parkinson’s: an industrial age disease [transcript]. Living on Earth. August 15, 1997. www.loe.org/shows/segments.html?programID=97-P13-00033&segmentID=1. Accessed March 26, 2019.
2. Poskanzer DC, Schwab RS. Studies in the epidemiology of Parkinson’s disease predicting its disappearance as a major clinical entity by 1980. Transactions of the American Neurological Association. 1961;86:234–235.
3. Constantin von Economo. Wikipedia. https://en.wikipedia.org/wiki/Constantin_von_Economo. Accessed February 15, 2019; Sak J, Grzybowski A. Brain and aviation: on the 80th anniversary of Constantin von Economo’s (1876–1931) death. Neurological Sciences. 2013;34(3):387–391.
4. Dickman MS. von Economo encephalitis. Archives of Neurology. 2001;58(10):1696–1698.
5. Lutters B, Foley P, Koehler PJ. The centennial lesson of encephalitis lethargica. Neurology. 2018;90(12):563–567.
6. Vilensky JA, Hoffman LA. Encephalitis lethargica: 100 years after the epidemic. Brain. 2017;140(8):2246–2251.
7. Sak J, Grzybowski A. Brain and aviation: on the 80th anniversary of Constantin von Economo’s (1876–1931) death. Neurological Sciences. 2013;34(3):387–391; Dickman MS. von Economo encephalitis. Archives of Neurology. 2001;58(10):1696–1698; Estupinan D, Nathoo S, Okun MS. The demise of Poskanzer and Schwab’s influenza theory on the pathogenesis of Parkinson’s disease. Parkinson’s Disease. 2013;2013:167843.
8. Lutters B, Foley P, Koehler PJ. The centennial lesson of encephalitis lethargica. Neurology. 2018;90(12):563–567.
9. Sacks O. Awakenings. Rpt. ed. Vintage; 1999.
10. Ibid.
11. Ibid.
12. Ibid.
13. Poskanzer DC, Schwab RS. Studies in the epidemiology of Parkinson’s disease predicting its disappearance as a major clinical entity by 1980. Transactions of the American Neurological Association. 1961;86:234–235.
14. The Parkinson’s puzzle. Time. 1974;104:71.
15. Moore G. Influenza and Parkinson’s disease. Public Health Reports. 1977;92(1):79–80.
16. Hoehn MM. Age distribution of patients with Parkinsonism. Journal of the American Geriatrics Society. 1976;24(2):79–85.
17. Margaret “Peggy” Hoehn M.D. Denver Post. July 22, 2005;Obituary.
18. GBD 2016 Parkinson’s Disease Collaborators. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology. 2018;17(11):939–953.
19. Muangpaisan W, Hori H, Brayne C. Systematic review of the prevalence and incidence of Parkinson’s disease in Asia. Journal of Epidemiology. 2009;19(6):281–293.
20. Goldman SM. Environmental toxins and Parkinson’s disease. Annual Review of Pharmacology and Toxicology. 2014;54(1):141–164.
21. Tilman D, Cassman KG, Matson PA, Naylor R, Polasky S. Agricultural sustainability and intensive production practices. Nature. 2002;418:671–677.
22. FAOSTAT: pesticides. Food and Agriculture Organization of the United Nations. www.fao.org/faostat/en/#data/EP/visualize. Accessed February 15, 2019.
23. Ibid.
24. Tilman D, Cassman KG, Matson PA, Naylor R, Polasky S. Agricultural sustainability and intensive production practices. Nature. 2002;418:671–677.
25. Rutchik JS. Organic solvent neurotoxicity. Medscape. https://emedicine.medscape.com/article/1174981-overview. Updated December 11, 2018. Accessed February 15, 2019.
26. Solvents. ChemicalSafetyFacts.org. www.chemicalsafetyfacts.org/solvents. Accessed March 26, 2019.
27. Dick FD. Solvent neurotoxicity. Occupational and Environmental Medicine. 2006;63(3):221–226.
28. C2 chlorinated solvents. IHS Markit. October 2017. https://ihsmarkit.com/products/c2-chlorinated-chemical-economics-handbook.html. Accessed March 26, 2019.
29. Ritz B, Lee P-C, Hansen J, et al. Traffic-related air pollution and Parkinson’s disease in Denmark: a case-control study. Environmental Health Perspectives. 2016;124(3):351–356; Doty RL. Olfactory dysfunction in Parkinson disease. Nature Reviews Neurology. 2012;8:329–339; Calderón-Garcidueñas L, Azzarelli B, Acuna H, et al. Air pollution and brain damage. Toxicologic Pathology. 2002;30(3):373–389.
30. GBD 2016 Parkinson’s Disease Collaborators. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology. 2018;17(11):939–953.
31. Rocheleau M. Chart: the percentage of women and men in each profession. Boston Globe. March 6, 2017. www.bostonglobe.com/metro/2017/03/06/chart-the-percentage-women-and-men-each-profession/GBX22YsWl0XaeHghwXfE4H/story.html. Accessed February 15, 2019.
32. GBD 2016 Parkinson’s Disease Collaborators. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology. 2018;17(11):939–953; Van Den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. American Journal of Epidemiology. 2003;157(11):1015–1022; Wooten GF, Currie LJ, Bovbjerg VE, Lee JK, Patrie J. Are men at greater risk for Parkinson’s disease than women? Journal of Neurology, Neurosurgery & Psychiatry. 2004;75(4):637–639; Mayeux R, Marder K, Cote LJ, et al. The frequency of idiopathic Parkinson’s disease by age, ethnic group, and sex in northern Manhattan, 1988–1993. American Journal of Epidemiology. 1995;142(8):820–827.
33. Roser M. Life expectancy. Our World in Data. https://ourworldindata.org/life-expectancy. Accessed March 31, 2019.
34. Ibid.
35. Paid notice: Deaths: Hoehn, Professor Margaret “Peggy,” M.D. New York Times. July 24, 2005: 1001032.
36. International programs: International Data Base. US Census Bureau. www.census.gov/data-tools/demo/idb/informationGateway.php. Updated: September 2018. Accessed November 19, 2018; Population ages 65 and above, total. World Bank. https://data.worldbank.org/indicator/SP.POP.65UP.To. Accessed November 19, 2018.
37. Levy G. The relationship of Parkinson disease with aging. Archives of Neurology. 2007;64(9):1242–1246.
38. Savica R, Rocca WA, Ahlskog JE. When does Parkinson disease start? Archives of Neurology. 2010;67(7):798–801.
39. Van Den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. American Journal of Epidemiology. 2003;157(11):1015–1022. www.ncbi.nlm.nih.gov/pubmed/12777365.
40. Scutti S. Drug overdoses, suicides cause drop in 2017 US life expectancy; CDC director calls it a “wakeup call.” CNN. December 17, 2018. www.cnn.com/2018/11/29/health/life-expectancy-2017-cdc/index.html. Accessed February 15, 2019; Naik G. Global life expectancy increases by about six years: study in Lancet says rise is results of dramatic health-care advances. Wall Street Journal. December 18, 2014; Murray CJL, Barber RM, Foreman KJ, et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. The Lancet. 2015;386(10009):2145–2191.
41. Wanneveich M, Moisan F, Jacqmin-Gadda H, Elbaz A, Joly P. Projections of prevalence, lifetime risk, and life expectancy of Parkinson’s disease (2010–2030) in France. Movement Disorders. 2018;33(9):1449–1455.
42. Proctor RN. The history of the discovery of the cigarette–lung cancer link: evidentiary traditions, corporate denial, global toll. Tobacco Control. 2012;21(2):87–91.
43. Ibid.
44. Ibid.; Lung cancer. Wikipedia. https://en.wikipedia.org/wiki/Lung_cancer. Accessed February 15, 2019.
45. Keating C. Smoking Kills: The Revolutionary Life of Richard Doll. Oxford: Signal Books; 2009.
46. Doll R, Hill AB. Lung cancer and other causes of death in relation to smoking; a second report on the mortality of British doctors. BMJ. 1956;2(5001):1071–1081.
47. Proctor RN. The history of the discovery of the cigarette–lung cancer link: evidentiary traditions, corporate denial, global toll. Tobacco Control. 2012;21(2):87–91.
48. Flanders WD, Lally CA, Zhu B-P, Henley SJ, Thun MJ. Lung cancer mortality in relation to age, duration of smoking, and daily cigarette consumption. Cancer Research. 2003;63(19):6556–6562.
49. Pesch B, Kendzia B, Gustavsson P, et al. Cigarette smoking and lung cancer—relative risk estimates for the major histological types from a pooled analysis of case-control studies. International Journal of Cancer. 2012;131(5):1210–1219.
50. GBD 2016 Parkinson’s Disease Collaborators. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology. 2018;17(11):939–953; Li X, Li W, Liu G, Shen X, Tang Y. Association between cigarette smoking and Parkinson’s disease: a meta-analysis. Archives of Gerontology and Geriatrics. 2015;61(3):510–516.
51. Ma C, Liu Y, Neumann S, Gao X. Nicotine from cigarette smoking and diet and Parkinson disease: a review. Translational Neurodegeneration. 2017;6:18; Maggio R, Riva M, Vaglini F, et al. Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors. Journal of Neurochemistry. 1998;71(6):2439–2446; Allam MF, Serrano del Castillo A, Fernandez-Crehuet Navajas R. Smoking and Parkinson’s disease: explanatory hypothesis. International Journal of Neuroscience. 2002;112(7):851–854; Miksys S, Tyndale RF. Nicotine induces brain CYP enzymes: relevance to Parkinson’s disease. Journal of Neural Transmission, Supplement. 2006(70):177–180.
52. Biedermann L, Zeitz J, Mwinyi J, et al. Smoking cessation induces profound changes in the composition of the intestinal microbiota in humans. PLOS ONE. 2013;8(3):e59260; Scheperjans F, Pekkonen E, Kaakkola S, Auvinen P. Linking smoking, coffee, urate, and Parkinson’s disease—a role for gut microbiota? Journal of Parkinson’s Disease. 2015;5(2):255–262.
53. Pagliuca G, Rosato C, Martellucci S, et al. Cytologic and functional alterations of nasal mucosa in smokers: temporary or permanent damage? Otolaryngology—Head and Neck Surgery. 2015;152(4):740–745; Utiyama DMO, Yoshida CT, Goto DM, et al. The effects of smoking and smoking cessation on nasal mucociliary clearance, mucus properties and inflammation. Clinics. 2016;71(6):344–350; Martin EM, Clapp PW, Rebuli ME, et al. E-cigarette use results in suppression of immune and inflammatory-response genes in nasal epithelial cells similar to cigarette smoke. American Journal of Physiology—Lung Cellular and Molecular Physiology. 2016;311(1):L135–L144.
54. Scheperjans F, Pekkonen E, Kaakkola S, Auvinen P. Linking smoking, coffee, urate, and Parkinson’s disease—a role for gut microbiota? Journal of Parkinson’s Disease. 2015;5(2):255–262; Derkinderen P, Shannon KM, Brundin P. Gut feelings about smoking and coffee in Parkinson’s disease. Movement Disorders. 2014;29(8):976–979.
55. Hopfner F, Künstner A, Müller SH, et al. Gut microbiota in Parkinson disease in a northern German cohort. Brain Research. 2017;1667:41–45; Tremlett H, Bauer KC, Appel-Cresswell S, Finlay BB, Waubant E. The gut microbiome in human neurological disease: a review. Annals of Neurology. 2017;81(3):369–382; Hasegawa S, Goto S, Tsuji H, et al. Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson’s disease. PLOS ONE. 2015;10(11):e0142164; Keshavarzian A, Green SJ, Engen PA, et al. Colonic bacterial composition in Parkinson’s disease. Movement Disorders. 2015;30(10):1351–1360.
56. Scheperjans F, Pekkonen E, Kaakkola S, Auvinen P. Linking Smoking, Coffee, Urate, and Parkinson’s Disease—A Role for Gut Microbiota? Journal of Parkinson’s Disease. 2015;5(2):255–262.
57. Sampson TR, Debelius JW, Thron T, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease. Cell. 2016;167(6):1469–1480.e12.
58. Ibid.
59. Health risks of smoking tobacco. American Cancer Society. Cancer A–Z. www.cancer.org/cancer/cancer-causes/tobacco-and-cancer/health-risks-of-smoking-tobacco.html. Accessed February 15, 2019.
60. Dorsey ER, Sherer T, Okun M, Bloem BR. The emerging evidence of the Parkinson pandemic. Journal of Parkinson’s Disease. 2018;8(Suppl 1):S3–S8.
61. Morris AD, Rose FC. James Parkinson: His Life and Times. Birkhauser; 1989.
62. Omran AR. The epidemiologic transition: a theory of the epidemiology of population change. Milbank Quarterly. 2005;83(4):731–757.
63. Fauci AS, Morens DM, Folkers GK. What is a Pandemic? Journal of Infectious Diseases. 2009;200(7):1018–1021.
64. Black death. Wikipedia. https://en.wikipedia.org/wiki/Black_Death. Accessed February 15, 2019.
65. Barry JM. The Great Influenza: The Story of the Deadliest Pandemic in History. Rev. ed: Penguin Books; 2005.
66. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet. 2012;380(9859):2095–2128.
67. Omran AR. The epidemiologic transition: a theory of the epidemiology of population change. Milbank Quarterly. 2005;83(4):731–757.
68. Olshansky SJ, Ault AB. The fourth stage of the epidemiologic transition: the age of delayed degenerative diseases. Milbank Quarterly. 1986;64(3):355–391.
69. Allen L. Are we facing a noncommunicable disease pandemic? Journal of Epidemiology and Global Health. 2017;7(1):5–9.
70. Fauci AS, Morens DM, Folkers GK. What is a Pandemic? Journal of Infectious Diseases. 2009;200(7):1018–1021.
71. GBD 2016 Parkinson’s Disease Collaborators. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology. 2018;17(11):939–953.
72. Ibid.
73. Gage H, Hendricks A, Zhang S, Kazis L. The relative health related quality of life of veterans with Parkinson’s disease. Journal of Neurology, Neurosurgery, and Psychiatry. 2003;74(2):163–169.
74. Kochanek KD, Murphy SL, Xu J, Tejada-Vera B. Deaths: Final Data for 2014. US Department of Health and Human Services; June 30, 2016.
75. FAOSTAT: pesticides. Food and Agriculture Organization of the United Nations. www.fao.org/faostat/en/#data/EP/visualize. Accessed February 15, 2019; Friesen MC, Locke SJ, Chen Y-C, et al. Historical occupational trichloroethylene air concentrations based on inspection measurements from Shanghai, China. Annals of Occupational Hygiene. 2015;59(1):62–78; Tang Z. The characteristics of urban air pollution in China. In: Urbanization, Energy, and Air Pollution in China: The Challenges Ahead: Proceedings of a Symposium. National Academies Press; 2004:47–54.
76. GBD 2016 Parkinson’s Disease Collaborators. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology. 2018;17(11):939–953.
77. Parashos SA, Maraganore DM, O’Brien PC, Rocca WA. Medical services utilization and prognosis in Parkinson disease: a population-based study. Mayo Clinic Proceedings. 2002;77(9):918–925; Gage H, Hendricks A, Zhang S, Kazis L. The relative health related quality of life of veterans with Parkinson’s disease. Journal of Neurology, Neurosurgery, and Psychiatry. 2003;74(2):163–169; Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson’s disease: a population-based, prospective study. Journal of the American Geriatrics Society. 2000;48(8):938–942; Dorsey ER, Deuel LM, Voss TS, et al. Increasing access to specialty care: a pilot, randomized controlled trial of telemedicine for Parkinson’s disease. Movement Disorders. 2010;25(11):1652–1659.
78. Hinz M, Stein A, Cole T. The Parkinson’s disease death rate: carbidopa and vitamin B6. Journal of Clinical Pharmacology. 2014;6:161–169.
1. Furnish D. To those who stood against AIDS apathy: thank you. Huffington Post. November 8, 2013.
2. Litsky F, Weber B. Roger Bannister, first athlete to break the 4-minute mile, is dead at 88. New York Times. March 5, 2018; Ingle S. Interview: Roger Bannister turns clock back 60 years and still feels the thrill. The Running Blog. Guardian. May 5, 2014; Crouch I. Roger Bannister’s solitary pursuit of the four-minute mile. New Yorker. March 5, 2018.
3. Guinness World Records. First sub–four minute mile—Sir Roger Bannister—Guinness World Records 60th anniversary [video file]. YouTube. December 8, 2014. www.youtube.com/watch?v=ku1vdrWQuJY.
4. Ibid.
5. Bannister R. Roger Bannister: “The day I broke the four-minute mile.” Daily Telegraph. March 30, 2014.
6. Litsky F, Weber B. Roger Bannister, first athlete to break the 4-minute mile, is dead at 88. New York Times. March 5, 2018; Roger Bannister. In: Dana R. Barnes, ed. Notable Sports Figures. Vol 1. Gale Group; 2004:86.
7. Limb M. Roger Gilbert Bannister: innovative neurologist and the first athlete to run a mile in less than four minutes. BMJ. 2018;361:k1589.
8. Litsky F, Weber B. Roger Bannister, first athlete to break the 4-minute mile, is dead at 88. New York Times. March 5, 2018.
9. Oshinsky DM. Polio: An American Story. Oxford University Press; 2006.
10. Ibid.
11. Ibid.
12. Goldman AS, Schmalstieg EJ, Freeman DH, Goldman DA, Schmalstieg FC. What was the cause of Franklin Delano Roosevelt’s paralytic illness? Journal of Medical Biography. 2003;11(4):232–240.
13. Oshinsky DM. Polio: An American Story. Oxford University Press; 2006.
14. Ibid.
15. Ibid.
16. Ibid.
17. Ibid.
18. Ibid.
19. Ibid.
20. Ibid.
21. Admin. History of health care. What If America Had a Healthcare System That Worked? December 20, 2009. http://whatifpost.com/health-care-resources/history-of-health-care.
22. Oshinsky DM. Polio: An American Story. Oxford University Press; 2006.
23. Moore W. Paralysed with fear: the story of polio by Gareth Williams—review. Guardian. July 17, 2013;Culture.
24. Poliomyelitis. Wikipedia. https://en.wikipedia.org/wiki/Poliomyelitis. Accessed October 15, 2018.
25. Resnick B. What America looked like: polio children paralyzed in iron lungs. Atlantic. January 10, 2012.
26. Press TA. Woman dies after life spent in iron lung. CNN. 2008. https://web.archive.org/web/20081022162511/http:/www.cnn.com/2008/US/05/28/iron.lung.death.ap/index.html. Updated May 28. Accessed March 4, 2019.
27. Meldrum M. “A calculated risk”: the Salk polio vaccine field trials of 1954. BMJ. 1998;317(7167):1233–1236.
28. Global Citizen. Could you patent the sun? [video file]. YouTube. January 29, 2013. www.youtube.com/watch?v=erHXKP386Nk.
29. Polio vaccine. Wikipedia. https://en.wikipedia.org/wiki/Polio_vaccine. Accessed October 15, 2018.
30. Oshinsky DM. Polio: An American Story. Oxford University Press; 2006.
31. Altman LK. Rare cancer seen in 41 homosexuals. New York Times. July 3, 1981:A00020.
32. Gupta RK, Abdul-Jawad S, McCoy LE, et al. HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation. Nature. 2019;568(7751):244–248.
33. Roser M, Ritchie H. HIV/AIDS. Our World in Data. November 2014. https://ourworldindata.org/hiv-aids. Updated April 2018. Accessed March 31, 2019.
34. Lopez G. The Reagan administration’s unbelievable response to the HIV/AIDS epidemic. Vox. December 1, 2016. www.vox.com/2015/12/1/9828348/ronald-reagan-hiv-aids. Accessed May 19, 2019.
35. Villarica H. 30 years of AIDS: 6,200 iconic posters, 100 countries, 1 collector. Atlantic. November 30, 2011; These posters show what AIDS meant in the 1980s. BuzzFeed.News. December 1, 2015. www.buzzfeednews.com/article/patrickstrudwick/these-1980s-aids-posters-show-the-desperate-fight-to-save-li. Accessed March 26, 2019; Schulman S. When protest movements became brands. New York Times. April 16, 2018.
36. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. New England Journal of Medicine. 2011;365(6):493–505; Treatment as prevention (TASP) for HIV. AVERT. www.avert.org/professionals/hiv-programming/prevention/treatment-as-prevention. Updated August 15, 2017. Accessed September 20, 2018.
37. Roser M, Ritchie H. HIV/AIDS. Our World in Data. November 2014. https://ourworldindata.org/hiv-aids. Updated April 2018. Accessed March 31, 2019.
38. When doctors refuse to treat AIDS. New York Times. August 3, 1987:A00016.
39. France D. How to Survive a Plague: The Inside Story of How Citizens and Science Tamed AIDS. Knopf; 2016.
40. Chang K. Q&A with David France. Anthem. September 20, 2012.
41. France D. How to Survive a Plague: The Inside Story of How Citizens and Science Tamed AIDS. Knopf; 2016.
42. Ryan’s story. Ryan White 1971–1990. https://ryanwhite.com/Ryans_Story.html. Accessed March 27, 2019.
43. Ryan White CARE Act. Wikipedia. https://en.wikipedia.org/wiki/Ryan_White_CARE_Act. Accessed September 20, 2018.
44. The AIDS Memorial Quilt. The NAMES Project Foundation. www.aidsquilt.org/about/the-aids-memorial-quilt. Accessed September 2018; Jones C. How one man’s idea for the AIDS quilt made the country pay attention. Washington Post. October 9, 2016; The AIDS Memorial Quilt. World Quilts: The American Story. http://worldquilts.quiltstudy.org/americanstory/engagement/NAMESquilt. Accessed March 5, 2019; Licostie N. The last one: the story of the AIDS Memorial Quilt. POZ. February 4, 2014. www.poz.com/article/nadine-licostie-25129-4218. Accessed March 5, 2019.
45. The AIDS Memorial Quilt. The NAMES Project Foundation. www.aidsquilt.org/about/the-aids-memorial-quilt. Accessed September 2018.
46. France D. How to Survive a Plague: The Inside Story of How Citizens and Science Tamed AIDS. Knopf; 2016.
47. The AIDS Memorial Quilt. The NAMES Project Foundation. www.aidsquilt.org/about/the-aids-memorial-quilt. Accessed September 2018.
48. Park A. The story behind the first AIDS drug. Time. March 19, 2017.
49. Ibid.
50. France D. How to survive a plague [film]. Sundance Selects. January 22, 2012. www.amazon.com/How-Survive-Plague-Peter-Staley/dp/B00A92MGLA; Peter Staley. Wikipedia. https://en.wikipedia.org/wiki/Peter_Staley. Accessed September 20, 2018.
51. Murphy T. Where are they now? ACT UP AIDS activists 25 years later. New York. June 25, 2013. http://nymag.com/intelligencer/2013/06/act-up-aids-activists-25-years-later.html. Accessed March 27, 2019.
52. Crimp D. Before Occupy: how AIDS activists seized control of the FDA in 1988. Atlantic. December 6, 2011.
53. France D. How to survive a plague [film]. Sundance Selects. January 22, 2012. www.amazon.com/How-Survive-Plague-Peter-Staley/dp/B00A92MGLA; Crimp D. Before Occupy: how AIDS activists seized control of the FDA in 1988. Atlantic. December 6, 2011.
54. Estimates of funding for various research, condition, and disease categories (RCDC). National Institutes of Health. 2018. https://report.nih.gov/categorical_spending.aspx. Updated May 18, 2018. Accessed March 31, 2019.
55. FDA approval of HIV medicines. US Department of Health and Human Services. AIDSinfo. https://aidsinfo.nih.gov/understanding-hiv-aids/infographics/25/fda-approval-of-hiv-medicines. Updated September 20, 2018. Accessed December 3, 2018.
56. Land E. Why do some HIV drugs cost so much? Pharma, insurers, advocacy groups and consumers weigh in. BETA Blog. October 28, 2015. www.sfaf.org/collections/beta/why-are-hiv-meds-so-expensive-and-what-can-we-do-about-it. Accessed June 27, 2019.
57. Jesse Helms. Wikipedia. https://en.wikipedia.org/wiki/Jesse_Helms. Accessed September 21, 2018.
58. France D. How to Survive a Plague: The Inside Story of How Citizens and Science Tamed AIDS. Knopf; 2016.
59. In memory of Jesse Helms, and the condom on his house. July 8, 2008. POZ. www.poz.com/blog/in-memory-of-je. Accessed September 21, 2018.
60. Ibid.
61. Ibid.
62. Ibid.
63. Accelerating towards 90-90-90. UNAIDS. July 24, 2018. www.unaids.org/en/resources/presscentre/featurestories/2018/july/90-90-90-targets-workshop. Accessed September 21, 2018.
64. Ibid.
65. Schneider AP, Zainer CM, Kubat CK, Mullen NK, Windisch AK. The breast cancer epidemic: 10 facts. Linacre Quarterly. 2014;81(3):244–277; King S. Pink Ribbons, Inc.: Breast Cancer and the Politics of Philanthropy. 1st ed. University of Minnesota Press; 2008; Rising global cancer epidemic. American Cancer Society. 2018. www.cancer.org/research/infographics-gallery/rising-global-cancer-epidemic.html. Accessed March 31, 2019.
66. Lerner BH. Not so simple: the breast cancer stories of Betty Ford and Happy Rockefeller. Huffington Post. September 26, 2014.
67. Betty Ford. Wikipedia. https://en.wikipedia.org/wiki/Betty_Ford. Accessed September 21, 2018.
68. Lerner BH. Not so simple: the breast cancer stories of Betty Ford and Happy Rockefeller. Huffington Post. September 26, 2014.
69. Betty Ford. Wikipedia. https://en.wikipedia.org/wiki/Betty_Ford. Accessed September 21, 2018.
70. Osuch JR, Silk K, Price C, et al. A historical perspective on breast cancer activism in the United States: from education and support to partnership in scientific research. Journal of Women’s Health. 2012;21(3):355–362.
71. Lorde A. A Burst of Light. Firebrand Books; 1988.
72. King S. Pink Ribbons, Inc.: Breast Cancer and the Politics of Philanthropy. 1st ed. University of Minnesota Press; 2008; Lorde A. The Cancer Journals: Special Edition. Aunt Lute Books; 2006.
73. Osuch JR, Silk K, Price C, et al. A historical perspective on breast cancer activism in the United States: from education and support to partnership in scientific research. Journal of Women’s Health. 2012;21(3):355–362.
74. Komen Race for the Cure. Susan G. Komen Minnesota. 2018. www.komenminnesota.org/komen_race_for_the_cure_.htm. Accessed March 5, 2019.
75. Annual Report Fiscal Year 2017. Susan G. Komen; 2018.
76. In memoriam: Charlotte Haley, creator of the first (peach) breast cancer ribbon. Breast Cancer Action. June 24, 2014. www.bcaction.org/2014/06/24/in-memoriam-charlotte-haley-creator-of-the-first-peach-breast-cancer-ribbon. Accessed March 5, 2019.
77. King S. Pink Ribbons, Inc.: Breast Cancer and the Politics of Philanthropy. 1st ed. University of Minnesota Press; 2008; Quinn A. Before pink became synonymous with breast cancer, there was peach. Podcast: 8:21. WHYY. July 23, 2015. https://whyy.org/segments/before-pink-became-synonymous-with-breast-cancer-there-was-peach. Accessed March 31, 2019.
78. King S. Pink Ribbons, Inc.: Breast Cancer and the Politics of Philanthropy. 1st ed. University of Minnesota Press; 2008; Quinn A. Before pink became synonymous with breast cancer, there was peach. Podcast: 8:21. WHYY. July 23, 2015. https://whyy.org/segments/before-pink-became-synonymous-with-breast-cancer-there-was-peach. Accessed March 31, 2019.
79. King S. Pink Ribbons Inc: breast cancer activism and the politics of philanthropy. International Journal of Qualitative Studies in Education. 2004;17(4):473–492.
80. Estimates of funding for various research, condition, and disease categories (RCDC). National Institutes of Health. 2018. https://report.nih.gov/categorical_spending.aspx. Updated May 18, 2018. Accessed March 31, 2019.
81. Breast Cancer Facts & Figures 2017–2018. American Cancer Society; 2017. www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2017-2018.pdf; US Breast Cancer Statistics. Breastcancer.org. 2018. www.breastcancer.org/symptoms/understand_bc/statistics. Last updated February 13, 2019. Accessed March 31, 2019.
1. Carson R, Darling L, Darling L. Silent Spring. Houghton Mifflin; 1962.
2. DDT—a brief history and status. US Environmental Protection Agency. www.epa.gov/ingredients-used-pesticide-products/ddt-brief-history-and-status. Updated August 11, 2017. Accessed March 25, 2019.
3. Public health statement for DDT, DDE, and DDD. Agency for Toxic Substances and Disease Registry. Toxic Substances Portal. September 2002. www.atsdr.cdc.gov/phs/phs.asp?id=79&tid=20. Accessed March 31, 2019.
4. Fleming L, Mann JB, Bean J, Briggle T, Sanchez-Ramos JR. Parkinson’s disease and brain levels of organochlorine pesticides. Annals of Neurology. 1994;36(1):100–103; Weisskopf MG, Knekt P, O’Reilly EJ, et al. Persistent organochlorine pesticides in serum and risk of Parkinson disease. Neurology. 2010;74(13):1055–1061; Freire C, Koifman S. Pesticide exposure and Parkinson’s disease: epidemiological evidence of association. NeuroToxicology. 2012;33(5):947–971.
5. Public health statement for DDT, DDE, and DDD. Agency for Toxic Substances and Disease Registry. Toxic Substances Portal. September 2002. www.atsdr.cdc.gov/phs/phs.asp?id=79&tid=20. Accessed March 31, 2019; Saeedi Saravi SS, Dehpour AR. Potential role of organochlorine pesticides in the pathogenesis of neurodevelopmental, neurodegenerative, and neurobehavioral disorders: a review. Life Sciences. 2016;145:255–264; Rossi M, Scarselli M, Fasciani I, Maggio R, Giorgi F. Dichlorodiphenyltrichloroethane (DDT) induced extracellular vesicle formation: a potential role in organochlorine increased risk of Parkinson’s disease. Acta Neurobiologiae Experimentalis. 2017;77(2):113–117.
6. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Richardson RJ. The risk of Parkinson’s disease with exposure to pesticides, farming, well water, and rural living. Neurology. 1998;50(5):1346–1350; Tüchsen F, Jensen AA. Agricultural work and the risk of Parkinson’s disease in Denmark, 1981–1993. Scandinavian Journal of Work, Environment & Health. 2000;26(4):359–362; Elbaz A, Clavel J, Rathouz PJ, et al. Professional exposure to pesticides and Parkinson disease. Annals of Neurology. 2009;66(4):494–504.
7. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Richardson RJ. The risk of Parkinson’s disease with exposure to pesticides, farming, well water, and rural living. Neurology. 1998;50(5):1346–1350.
8. Elbaz A, Clavel J, Rathouz PJ, et al. Professional exposure to pesticides and Parkinson disease. Annals of Neurology. 2009;66(4):494–504.
9. Kab S, Spinosi J, Chaperon L, et al. Agricultural activities and the incidence of Parkinson’s disease in the general French population. European Journal of Epidemiology. 2017;32(3):203–216; Strickland D, Bertoni JM. Parkinson’s prevalence estimated by a state registry. Movement Disorders. 2004;19(3):318–323; Martino R, Candundo H, Lieshout PV, Shin S, Crispo JAG, Barakat-Haddad C. Onset and progression factors in Parkinson’s disease: a systematic review. NeuroToxicology. 2017;61:132–141.
10. Ames RG, Howd RA, Doherty L. Community exposure to a paraquat drift. Archives of Environmental Health: An International Journal. 1993;48(1):47–52.
11. Martino R, Candundo H, Lieshout PV, Shin S, Crispo JAG, Barakat-Haddad C. Onset and progression factors in Parkinson’s disease: a systematic review. NeuroToxicology. 2017;61:132–141; Gatto NM, Cockburn M, Bronstein J, Manthripragada AD, Ritz B. Well-water consumption and Parkinson’s disease in rural California. Environmental Health Perspectives. 2009;117(12):1912–1918; James KA, Hall DA. Groundwater pesticide levels and the association with Parkinson disease. International Journal of Toxicology. 2015;34(3):266–273.
12. Gatto NM, Cockburn M, Bronstein J, Manthripragada AD, Ritz B. Well-water consumption and Parkinson’s disease in rural California. Environmental Health Perspectives. 2009;117(12):1912–1918; Drinking water and pesticides. US Environmental Protection Agency. www.epa.gov/safepestcontrol/drinking-water-and-pesticides. Updated June 19, 2017. Accessed March 25, 2019.
13. Private drinking water wells. US Environmental Protection Agency. www.epa.gov/privatewells. Updated June 6, 2018. Accessed March 25, 2019; Private ground water wells. Centers for Disease Control and Prevention. www.cdc.gov/healthywater/drinking/private/wells/index.html. Last reviewed December 16, 2014. Accessed March 25, 2019; Water and pesticides. National Pesticide Information Center. http://npic.orst.edu/envir/water.html. Last updated January 13, 2016. Accessed March 25, 2019.
14. Strickland D, Bertoni JM. Parkinson’s prevalence estimated by a state registry. Movement Disorders. 2004;19(3):318–323.
15. Barbeau A, Roy M, Bernier G, Campanella G, Paris S. Ecogenetics of Parkinson’s disease: prevalence and environmental aspects in rural areas. Canadian Journal of Neurological Sciences. 1987;14(1):36–41.
16. Kab S, Spinosi J, Chaperon L, et al. Agricultural activities and the incidence of Parkinson’s disease in the general French population. European Journal of Epidemiology. 2017;32(3):203–216.
17. Haspel T. The truth about organic produce and pesticides. Daily Gazette. May 23, 2018.
18. DDT (general fact sheet). National Pesticide Information Center; 1999. http://npic.orst.edu/factsheets/ddtgen.pdf.
19. Berry-Caban CS. DDT and Silent Spring: fifty years after. Journal of Military and Veterans’ Health. 2011;19(4):19–24.
20. Bate R. The Rise, Fall, Rise, and Imminent Fall of DDT. American Enterprise Institute for Public Policy Research; November 5, 2007.
21. Whorton JC. Before Silent Spring: Pesticides and Public Health in Pre-DDT America. Princeton University Press; 2015.
22. DDT. Wikipedia. https://en.wikipedia.org/wiki/DDT. Accessed October 15, 2018; Rogan WJ, Chen A. Health risks and benefits of bis(4-chlorophenyl)-1,1,1-trichloroethane (DDT). The Lancet. 2005;366(9487):763–773; Dr. Paul Müller. Nature. 1965;208(5015):1043–1044; Paul Hermann Müller. Wikipedia. https://en.wikipedia.org/wiki/Paul_Hermann_M%C3%BCller. Accessed March 25, 2019.
23. Longnecker MP, Rogan WJ, Lucier G. The human health effects of DDT (dichlorodiphenyltrichloroethane) and PCBS (polychlorinated biphenyls) and an overview of organochlorines in public health. Annual Review of Public Health. 1997;18(1):211–244.
24. Snedeker SM. Pesticides and breast cancer risk: a review of DDT, DDE, and dieldrin. Environmental Health Perspectives. 2001;109(Suppl 1):35–47.
25. Longnecker MP, Rogan WJ, Lucier G. The human health effects of DDT (dichlorodiphenyltrichloroethane) and PCBS (polychlorinated biphenyls) and an overview of organochlorines in public health. Annual Review of Public Health. 1997;18(1):211–244.
26. Dichlorodiphenyltrichloroethane (DDT). Centers for Disease Control and Prevention; 2009. www.cdc.gov/biomonitoring/pdf/ddt_factsheet.pdf.
27. Pesticide information profile: DDT (dichlorodiphenyltrichloroethane). Extension Toxciology Network. http://pmep.cce.cornell.edu/profiles/extoxnet/carbaryl-dicrotophos/ddt-ext.html. Accessed March 25, 2019.
28. Stellman JM, Stellman SD, Christian R, Weber T, Tomasallo C. The extent and patterns of usage of Agent Orange and other herbicides in Vietnam. Nature. 2003;422:681–687.
29. Ibid.
30. Stone R. Agent Orange’s bitter harvest. Science. 2007;315(5809):176–179.
31. Yi S-W, Ohrr H, Hong J-S, Yi J-J. Agent Orange exposure and prevalence of self-reported diseases in Korean Vietnam veterans. Journal of Preventive Medicine and Public Health. 2013;46(5):213–225; Medicine Io. Veterans and Agent Orange: Update 2010. National Academies Press; 2012.
32. Parkinson’s disease and Agent Orange. US Department of Veterans Affairs: Public Health. www.publichealth.va.gov/exposures/agentorange/conditions/parkinsonsdisease.asp. Accessed March 25, 2019.
33. Hawaii recalls pesticide-laced milk from stores and schools. New York Times. March 20, 1982.
34. Contaminated milk problem in Hawaii nears end. New York Times. May 23, 1982; Smith RJ. Hawaiian milk contamination creates alarm. Science. 1982;217(4555):137–140.
35. Smith RJ. Hawaiian milk contamination creates alarm. Science. 1982;217(4555):137–140.
36. Ibid.
37. Hawaii recalls pesticide-laced milk from stores and schools. New York Times. March 20, 1982.
38. Ibid.; Contaminated milk problem in Hawaii nears end. New York Times. May 23, 1982.
39. Smith RJ. Hawaiian milk contamination creates alarm. Science. 1982;217(4555):137–140.
40. Ibid.
41. Ibid.
42. Abbott RD, Ross GW, Petrovitch H, et al. Midlife milk consumption and substantia nigra neuron density at death. Neurology. 2016;86(6):512–519.
43. Ibid.
44. Ibid.
45. Park A. Drinking milk is linked to Parkinson’s disease: study. Time. December 9, 2015.
46. Aldrin/dieldrin. Agency for Toxic Substances and Disease Registry. Toxic Substances Portal. www.atsdr.cdc.gov/substances/toxsubstance.asp?toxid=56. Last updated March 3, 2011. Accessed March 25, 2019; Aldrin and Dieldrin—ToxFAQs. Agency for Toxic Substances and Disease Registry; 2002. www.atsdr.cdc.gov/toxfaqs/tfacts1.pdf.
47. Fleming L, Mann JB, Bean J, Briggle T, Sanchez-Ramos JR. Parkinson’s disease and brain levels of organochlorine pesticides. Annals of Neurology. 1994;36(1):100–103; Richardson JR, Shalat SL, Buckley B, et al. Elevated serum pesticide levels and risk of Parkinson disease. Archives of Neurology. 2009;66(7):870–875; Corrigan FM, Wienburg CL, Shore RF, Daniel SE, Mann D. Organochlorine insecticides in substantia nigra in Parkinson’s disease. Journal of Toxicology and Environmental Health, Part A. 2000;59(4):229–234.
48. Sanchez-Ramos J, Facca A, Basit A, Song S. Toxicity of dieldrin for dopaminergic neurons in mesencephalic cultures. Experimental Neurology. 1998;150(2):263–271; Richardson JR, Caudle WM, Wang M, Dean ED, Pennell KD, Miller GW. Developmental exposure to the pesticide dieldrin alters the dopamine system and increases neurotoxicity in an animal model of Parkinson’s disease. FASEB Journal. 2006;20(10):1695–1697.
49. Wong MH, Leung AOW, Chan JKY, Choi MPK. A review on the usage of POP pesticides in China, with emphasis on DDT loadings in human milk. Chemosphere. 2005;60(6):740–752.
50. Ibid.
51. Ibid.; Sifuentes Dos Santos J, Schwanz TG, Coelho AN, et al. Estimated daily intake of organochlorine pesticides from dairy products in Brazil. Food Control. 2015;53:23–28; Kampire E, Kiremire BT, Nyanzi SA, Kishimba M. Organochlorine pesticide in fresh and pasteurized cow’s milk from Kampala markets. Chemosphere. 2011;84(7):923–927; Gebremichael S, Birhanu T, Tessema DA. Analysis of organochlorine pesticide residues in human and cow’s milk in the towns of Asendabo, Serbo and Jimma in south-western Ethiopia. Chemosphere. 2013;90(5):1652–1657.
52. Vall O, Gomez-Culebras M, Puig C, et al. Prenatal and postnatal exposure to DDT by breast milk analysis in Canary Islands. PLOS One. 2014;9(1):e83831–e83831; Kanthasamy AG, Kitazawa M, Kanthasamy A, Anantharam V. Dieldrin-induced neurotoxicity: relevance to Parkinson’s disease pathogenesis. NeuroToxicology. 2005;26(4):701–719; Chen M-W, Santos HM, Que DE, et al. Association between organochlorine pesticide levels in breast milk and their effects on female reproduction in a Taiwanese population. International Journal of Environmental Research and Public Health. 2018;15(5):931.
53. Jorgenson JL. Aldrin and dieldrin: a review of research on their production, environmental deposition and fate, bioaccumulation, toxicology, and epidemiology in the United States. Environmental Health Perspectives. 2001;109(Suppl 1):113–139.
54. Saeedi Saravi SS, Dehpour AR. Potential role of organochlorine pesticides in the pathogenesis of neurodevelopmental, neurodegenerative, and neurobehavioral disorders: a review. Life Sciences. 2016;145:255–264; Pesticide information profile: DDT (dichlorodiphenyltrichloroethane). Extension Toxciology Network. http://pmep.cce.cornell.edu/profiles/extoxnet/carbaryl-dicrotophos/ddt-ext.html. Accessed March 25, 2019; Gannon N, Link RP, Decker GC. Pesticide residues in milk, insecticide residues in the milk of dairy cows fed insecticides in their daily ration. Journal of Agricultural and Food Chemistry. 1959;7(12):829–832.
55. Liu J, Morrow AL, Devaud LL, Grayson DR, Lauder JM. Regulation of GABAA receptor subunit mRNA expression by the pesticide dieldrin in embryonic brainstem cultures: a quantitative, competitive reverse transcription-polymerase chain reaction study. Journal of Neuroscience Research. 1997;49(5):645–653.
56. Saeedi Saravi SS, Dehpour AR. Potential role of organochlorine pesticides in the pathogenesis of neurodevelopmental, neurodegenerative, and neurobehavioral disorders: a review. Life Sciences. 2016;145:255–264.
57. Tanner CM, Kamel F, Ross GW, et al. Rotenone, paraquat, and Parkinson’s disease. Environmental Health Perspectives. 2011;119(6):866–872; Dinis-Oliveira RJ, Remião F, Carmo H, et al. Paraquat exposure as an etiological factor of Parkinson’s disease. NeuroToxicology. 2006;27(6):1110–1122; Thiruchelvam M, McCormack A, Richfield EK, et al. Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson’s disease phenotype. European Journal of Neuroscience. 2003;18(3):589–600; Wang A, Costello S, Cockburn M, Zhang X, Bronstein J, Ritz B. Parkinson’s disease risk from ambient exposure to pesticides. European Journal of Epidemiology. 2011;26(7):547–555.
58. Hakim D. This pesticide is prohibited in Britain. Why is it still being exported? New York Times. December 20, 2016.
59. Paraquat benefits. Paraquat Information Center. https://paraquat.com/en/benefits. Accessed October 15, 2018.
60. Pesticide National Synthesis Project: estimated annual agricultural pesticide use. US Geological Survey. https://water.usgs.gov/nawqa/pnsp/usage/maps/show_map.php?year=2015&map=PARAQUAT&hilo=H. Updated September 11, 2018. Accessed March 25, 2019.
61. Ibid.
62. Ibid.
63. Ibid.
64. Costello S, Cockburn M, Bronstein J, Zhang X, Ritz B. Parkinson’s disease and residential exposure to maneb and paraquat from agricultural applications in the Central Valley of California. American Journal of Epidemiology. 2009;169(8):919–926.
65. Tanner CM, Kamel F, Ross GW, et al. Rotenone, paraquat, and Parkinson’s disease. Environmental Health Perspectives. 2011;119(6):866–872; Goldman SM, Kamel F, Ross GW, et al. Genetic modification of the association of paraquat and Parkinson’s disease. Movement Disorders. 2012;27(13):1652–1658.
66. Hakim D. This pesticide is prohibited in Britain. Why is it still being exported? New York Times. December 20, 2016.
67. Betarbet R, Sherer TB, Greenamyre JT. Animal models of Parkinson’s disease. BioEssays. 2002;24(4):308–318.
68. Brooks AI, Chadwick CA, Gelbard HA, Cory-Slechta DA, Federoff HJ. Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. Brain Research. 1999;823(1):1–10.
69. Watts M. Paraquat. Pesticide Action Network Asia & the Pacific. February 2011. www.panna.org/sites/default/files/Paraquat%20monograph%20final%202011-1.pdf. Accessed June 28, 2019.
70. Joyce M. Ocular damage caused by paraquat. British Journal of Ophthalmology. 1969;53(10):688–690.
71. Pesticide information profile: paraquat. Extension Toxicology Network. September 1993. http://pmep.cce.cornell.edu/profiles/extoxnet/metiram-propoxur/paraquat-ext.html. Accessed March 25, 2019.
72. Cha ES, Lee WJ, Chang S-S, Gunnell D, Eddleston M, Khang Y-H. Impact of paraquat regulation on suicide in South Korea. International Journal of Epidemiology. 2015;45(2):470–479; Lin C, Yen T-H, Juang Y-Y, Lee C-P, Lee S-H. Distinct psychopathology of patients who attempted suicide with rodenticide in Taiwan: a comparative study with patients of suicide with paraquat. Psychology Research and Behavior Management. 2018;11:323–328.
73. Hakim D. This pesticide is prohibited in Britain. Why is it still being exported? New York Times. December 20, 2016; Mercola J. Paraquat—banned in EU while US increasing use of this toxic killer. Mercola: Take Control of Your Health. January 3, 2017. https://articles.mercola.com/sites/articles/archive/2017/01/03/paraquat-banned-in-32-countries.aspx. Accessed May 20, 2019.
74. Hakim D. This pesticide is prohibited in Britain. Why is it still being exported? New York Times. December 20, 2016.
75. Ibid.
76. Watts M. Paraquat. Pesticide Action Network Asia & the Pacific. February 2011. www.panna.org/sites/default/files/Paraquat%20monograph%20final%202011-1.pdf. Accessed June 28, 2019.
77. Hakim D. This pesticide is prohibited in Britain. Why is it still being exported? New York Times. December 20, 2016.
78. FTC requires China National Chemical Corporation and Syngenta AG to divest U.S. assets as a condition of merger [press release]. Federal Trade Commission, April 4, 2017; McConnell W. ChemChina gets FTC OK to snap up Syngenta. TheStreet. April 4, 2017. www.thestreet.com/story/14073559/1/chemchina-gets-ftc-ok-to-snap-up-syngenta.html. Accessed September 20, 2018.
79. Concern over paraquat. “Re: Docket EPA-HQ-OPP-2011-0855 (paraquat dichloride registration review).” Michael J. Fox Foundation. July 24, 2017. https://files.michaeljfox.org/Paraquat_letter_FINAL.pdf; personal communication.
80. Paraquat dichloride: reregistration eligibility decision (RED) fact sheet. US Environmental Protection Agency. August 1997. https://archive.epa.gov/pesticides/reregistration/web/pdf/0262fact.pdf.
81. Paraquat Dichloride: One Sip Can Kill. US Environmental Protection Agency. Pesticide Worker Safety. www.epa.gov/pesticide-worker-safety/paraquat-dichloride-one-sip-can-kill. Last updated May 8, 2019. Accessed March 25, 2019.
82. Ibid.
83. Ibid.
84. Ibid.
85. The Michael J. Fox Foundation submits 107,000 community signatures urging the EPA to ban herbicide linked to Parkinson’s [press release]. The Michael J. Fox Foundation for Parkinson’s Research, February 6, 2019.
86. Ibid.
87. Pesticide National Synthesis Project: estimated annual agricultural pesticide use. US Geological Survey. https://water.usgs.gov/nawqa/pnsp/usage/maps/show_map.php?year=2015&map=PARAQUAT&hilo=H. Updated September 11, 2018. Accessed March 25, 2019.
88. Paraquat dichloride. US Environmental Protection Agency. www.epa.gov/ingredients-used-pesticide-products/paraquat-dichloride. Updated May 15, 2019. Accessed May 19, 2019.
89. Pesticide National Synthesis Project: estimated annual agricultural pesticide use. US Geological Survey. https://water.usgs.gov/nawqa/pnsp/usage/maps/show_map.php?year=2015&map=PARAQUAT&hilo=H. Updated September 11, 2018. Accessed March 25, 2019.
90. Furlong M, Tanner CM, Goldman SM, et al. Protective glove use and hygiene habits modify the associations of specific pesticides with Parkinson’s disease. Environment International. 2015;75:144–150.
91. Doll R, Hill AB. Lung cancer and other causes of death in relation to smoking; a second report on the mortality of British doctors. BMJ. 1956;2(5001):1071–1081; Doll R, Hill AB. The mortality of doctors in relation to their smoking habits: a preliminary report. BMJ. 1954;1(4877):1451–1455; Hill AB. The environment and disease: association or causation? Proceedings of the Royal Society of Medicine. 1965;58(5):295–300.
92. Hill AB. The environment and disease: association or causation? Proceedings of the Royal Society of Medicine. 1965;58(5):295–300; Fedak KM, Bernal A, Capshaw ZA, Gross S. Applying the Bradford Hill criteria in the 21st century: how data integration has changed causal inference in molecular epidemiology. Emerging Themes in Epidemiology. 2015;12:14.
93. Bates C, Rowell A. Tobacco Explained: The Truth About the Tobacco Industry. Action on Smoking and Health; 1998.
94. Hakim D, Lipton E. Pesticide studies won E.P.A.’s trust until Trump’s team scorned “secret science.” New York Times. August 24, 2018.
95. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nature Neuroscience. 2000;3(12):1301–1306; Sparling AS, Martin DW, Posey LB. An evaluation of the proposed worker protection standard with respect to pesticide exposure and Parkinson’s disease. International Journal of Environmental Research and Public Health. 2017;14(6):640; Van Maele-Fabry G, Hoet P, Vilain F, Lison D. Occupational exposure to pesticides and Parkinson’s disease: a systematic review and meta-analysis of cohort studies. Environment International. 2012;46:30–43; Gunnarsson L-G, Bodin L. Parkinson’s disease and occupational exposures: a systematic literature review and meta-analyses. Scandinavian Journal of Work, Environment & Health. 2017(3):197–209; Johnson ME, Bobrovskaya L. An update on the rotenone models of Parkinson’s disease: their ability to reproduce the features of clinical disease and model gene-environment interactions. NeuroToxicology. 2015;46:101–116; Petrovitch H, Ross G, Abbott RD, et al. Plantation work and risk of Parkinson disease in a population-based longitudinal study. Archives of Neurology. 2002;59(11):1787–1792.
96. Breckenridge CB, Berry C, Chang ET, Sielken RL, Jr., Mandel JS. Association between Parkinson’s disease and cigarette smoking, rural living, well-water consumption, farming and pesticide use: systematic review and meta-analysis. PLOS One. 2016;11(4):e0151841–e0151841.
97. Ibid.
98. Carson R, Darling L, Darling L. Silent Spring. Houghton Mifflin; 1962.
99. Ibid.
100. Ibid.
101. Aktar MW, Sengupta D, Chowdhury A. Impact of pesticides use in agriculture: their benefits and hazards. Interdisciplinary Toxicology. 2009;2(1):1–12; Cooper J, Dobson H. The benefits of pesticides to mankind and the environment. Crop Protection. 2007;26(9):1337–1348; Shelton JF, Hertz-Picciotto I, Pessah IN. Tipping the balance of autism risk: potential mechanisms linking pesticides and autism. Environmental Health Perspectives. 2012;120(7):944–951; Shelton JF, Geraghty EM, Tancredi DJ, et al. Neurodevelopmental disorders and prenatal residential proximity to agricultural pesticides: the CHARGE Study. Environmental Health Perspectives. 2014;122(10):1103–1109; Holzman DC. Pesticides and autism spectrum disorders: new findings from the CHARGE Study. Environmental Health Perspectives. 2014;122(10):A280–A280; Jee S-H, Kuo H-W, Su WPD, Chang C-H, Sun C-C, Wang J-D. Photodamage and skin cancer among paraquat workers. International Journal of Dermatology. 1995;34(7):466–469; Pesticide information profile: paraquat. Extension Toxicology Network. September 1993. http://pmep.cce.cornell.edu/profiles/extoxnet/metiram-propoxur/paraquat-ext.html. Accessed March 25, 2019.
102. Gatto NM, Cockburn M, Bronstein J, Manthripragada AD, Ritz B. Well-water consumption and Parkinson’s disease in rural California. Environmental Health Perspectives. 2009;117(12):1912–1918; Wang A, Costello S, Cockburn M, Zhang X, Bronstein J, Ritz B. Parkinson’s disease risk from ambient exposure to pesticides. European Journal of Epidemiology. 2011;26(7):547–555.
1. Hardmon T, Libert R. Semper fi: always faithful [film]. April 21, 2011.
2. Goldman SM, Quinlan PJ, Ross GW, et al. Solvent exposures and Parkinson disease risk in twins. Annals of Neurology. 2012;71(6):776–784.
3. IARC Working Group on the Evaluation of Carcinogenic Risk to Humans. Trichloroethylene, tetrachloroethylene, and some other chlorinated Agents. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans 106. Lyon: International Agency for Research on Cancer; 2014. Trichloroethylene. IDC Technologies. www.idc-online.com/technical_references/pdfs/chemical_engineering/Trichloroethylene.pdf. Accessed March 29, 2019.
4. ToxFAQs for trichloroethylene (TCE). Agency for Toxic Substances & Disease Registry. Toxic Substances Portal. www.atsdr.cdc.gov/toxfaqs/tf.asp?id=172&tid=30. Updated November 4, 2016. Accessed March 14, 2019; Trichloroethylene. Wikipedia. https://en.wikipedia.org/wiki/Trichloroethylene. Accessed March 14, 2019; Campbell-Dollaghan K. The secret history of Silicon Valley and the toxic remnants of the first computers. Gizmodo. November 20, 2015. https://gizmodo.com/the-secret-history-of-silicon-valley-and-the-toxic-remn-1743622225. Accessed March 14, 2019.
5. IARC Working Group on the Evaluation of Carcinogenic Risk to Humans. Trichloroethylene, tetrachloroethylene, and some other chlorinated agents. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. 2014;106:1–512.
6. Guehl D, Bezard E, Dovero S, Boraud T, Bioulac B, Gross C. Trichloroethylene and parkinsonism: a human and experimental observation. European Journal of Neurology. 1999;6(5):609–611.
7. TCE overview. Agency for Toxic Substances and Disease Registry. Trichloroethylene (TCE). www.atsdr.cdc.gov/tox-tool/trichloroethylene/01/tce_overview.html. Accessed March 29, 2019.
8. Risk management for trichloroethylene (TCE). US Environmental Protection Agency. www.epa.gov/assessing-and-managing-chemicals-under-tsca/risk-management-trichloroethylene-tce. Updated December 14, 2017. Accessed November 16, 2018.
9. James WR. Fatal addiction to trichloroethylene. British Journal of Industrial Medicine. 1963;20(1):47–49.
10. McCord CP. Toxicity of trichloroethylene. Journal of the American Medical Association. 1932;99(5):409.
11. Ibid.
12. Gash DM, Rutland K, Hudson NL, et al. Trichloroethylene: parkinsonism and complex 1 mitochondrial neurotoxicity. Annals of Neurology. 2008;63(2):184–192.
13. Ibid.
14. Ibid.
15. Ibid.
16. Ibid.
17. Barringer F. Exposed to solvent, worker faces hurdles. New York Times. January 24, 2009.
18. Barringer F. E.P.A. charts risks of a ubiquitous chemical. New York Times. September 30, 2011.
19. Goldman SM, Quinlan PJ, Ross GW, et al. Solvent exposures and Parkinson disease risk in twins. Annals of Neurology. 2012;71(6):776–784.
20. Ibid.
21. Freshwater LL. What happened at Camp Lejeune. In Pacific Standard. Social Justice Foundation; 2018; Marine Corps Base Camp Lejeune. Marines: The Official Website of the United States Marine Corps. www.lejeune.marines.mil/About. Accessed March 29, 2019.
22. Freshwater LL. What happened at Camp Lejeune. In Pacific Standard. Social Justice Foundation; 2018.
23. Goldman SM, Quinlan PJ, Ross GW, et al. Solvent exposures and Parkinson disease risk in twins. Annals of Neurology. 2012;71(6):776–784.
24. Nazaryan A. Camp Lejeune and the U.S. military’s polluted legacy. Newsweek. July 16, 2014.
25. ABC One Hour Cleaners Jacksonville, NC: Cleanup Activities. US Environmental Protection Agency. Superfund Site. https://cumulis.epa.gov/supercpad/SiteProfiles/index.cfm?fuseaction=second.cleanup&id=0402718. Updated October 23, 2018. Accessed March 29, 2019.
26. Council NR. Contaminated Water Supplies at Camp Lejeune: Assessing Potential Health Effects. National Academies Press; 2009.
27. Goldman SM, Quinlan PJ, Ross GW, et al. Solvent exposures and Parkinson disease risk in twins. Annals of Neurology. 2012;71(6):776–784; Council NR. Contaminated Water Supplies at Camp Lejeune: Assessing Potential Health Effects. National Academies Press; 2009.
28. Freshwater LL. What happened at Camp Lejeune. In Pacific Standard. Social Justice Foundation; 2018; Camp Lejeune: Contamination and Compensation, Looking Back, Moving Forward. US Government Publishing Office; 2010. www.govinfo.gov/content/pkg/CHRG-111hhrg58485/html/CHRG-111hhrg58485.htm.
29. Peeples L. Camp Lejeune water contamination cover-up hinted in navy letter. Huffington Post. January 13, 2012. www.huffpost.com/entry/camp-lejeune-water-contamination-navy-letter_n_1203465. Updated December 6, 2017. Accessed March 29, 2019.
30. Smithberger M. Watchdog: significant concerns regarding drinking water safety at navy bases overseas. Project on Government Oversight. August 9, 2017. www.pogo.org/investigation/2017/08/watchdog-significant-concerns-regarding-drinking-water-safety-at-navy-bases-overseas. Accessed March 29, 2019; Wagner A, Maurer K. A legacy of pain for Camp Lejeune water contamination victims. GateHouse Media. Star News Online. March 25, 2017. www.starnewsonline.com/news/20170325/legacy-of-pain-for-camp-lejeune-water-contamination-victims. Accessed March 29, 2019.
31. Camp Lejeune: Contamination and Compensation, Looking Back, Moving Forward. US Government Publishing Office; 2010. www.govinfo.gov/content/pkg/CHRG-111hhrg58485/html/CHRG-111hhrg58485.htm.
32. Ibid.
33. Ibid.
34. Freshwater LL. What happened at Camp Lejeune. In Pacific Standard. Social Justice Foundation; 2018; Camp Lejeune drinking water U.S. Marine Corps Base Camp Lejeune, North Carolina. Agency for Toxic Substances and Disease Registry. December 20, 2017. www.atsdr.cdc.gov/HAC/pha/MarineCorpsBaseCampLejeune/Camp_Lejeune_Drinking_Water_PHA(final)_%201-20-2017_508.pdf; Pipe A, Freshwater L. Poisoned by My Government: How the Military Let Families Drink Contaminated Water for Decades and Didn’t Learn from It. Craig Newmark Graduate School of Journalism, City University of New York; 2017.
35. Freshwater LL. What happened at Camp Lejeune. In Pacific Standard. Social Justice Foundation; 2018.
36. Ibid.; Freshwater LL. Medium. https://medium.com/@LFreshwater. Accessed March 29, 2019.
37. Freshwater LL. What happened at Camp Lejeune. In Pacific Standard. Social Justice Foundation; 2018.
38. Schrade B. Years later, marine families bear scars of poisoning at Camp Lejeune. Atlanta Journal-Constitution. February 23, 2018.
39. Kime P. The toxic homefront: as marine families fall ill, some are accusing the corps of negligence. Task & Purpose. April 19, 2017. https://taskandpurpose.com/the-toxic-homefront-as-marine-families-fall-ill-some-are-accusing-the-corps-of-negligence. Accessed March 29, 2019.
40. Affairs DoV. Diseases associated with exposure to contaminants in the water supply at Camp Lejeune. Federal Register. 2017;82(9).
41. Ibid.
42. Fisher J. Poison valley. Salon. 2001. www.salon.com/2001/07/30/almaden1. Updated July 31, 2001. Accessed March 29, 2019.
43. Campbell-Dollaghan K. The secret history of Silicon Valley and the toxic remnants of the first computers. Gizmodo. November 20, 2015. https://gizmodo.com/the-secret-history-of-silicon-valley-and-the-toxic-remn-1743622225. Accessed March 14, 2019; Chepesiuk R. Where the chips fall: environmental health in the semiconductor industry. Environmental Health Perspectives. 1999;107(9):452–457.
44. Superfund sites in reuse in California. US Environmental Protection Agency. Superfund Redevelopment Initiative. www.epa.gov/superfund-redevelopment-initiative/superfund-sites-reuse-california. Updated March 7, 2019. Accessed March 29, 2019; Fairchild Semiconductor Corp. (Mountain View Plant) Mountain View, CA: cleanup activities. US Environmental Protection Agency. 2018. https://cumulis.epa.gov/supercpad/SiteProfiles/index.cfm?fuseaction=second.Cleanup&id=0901680. Accessed March 31, 2019.
45. What is Superfund? US Environmental Protection Agency. www.epa.gov/superfund/what-superfund. Updated November 30, 2018. Accessed March 28, 2019.
46. Ibid.; Nazaryan A. The US Department of Defense is one of the world’s biggest polluters. Newsweek. July 17, 2014.
47. Superfund sites in reuse in California. US Environmental Protection Agency. Superfund Redevelopment Initiative. www.epa.gov/superfund-redevelopment-initiative/superfund-sites-reuse-california. Updated March 7, 2019. Accessed March 29, 2019.
48. Fairchild Semiconductor Corp. (Mountain View Plant) Mountain View, CA: cleanup activities. US Environmental Protection Agency. 2018. https://cumulis.epa.gov/supercpad/SiteProfiles/index.cfm?fuseaction=second.Cleanup&id=0901680. Accessed March 31, 2019.
49. Horton J. I live next to Google—and on top of a toxic site. Don’t let polluters be evil. Guardian. March 19, 2014.
50. Ibid.
51. Ibid.
52. DeBolt D. TCE causes cancer, other health problems, EPA says. Mountain View Voice. October 7, 2011; Hasan F. Residents near old semiconductor plant worry about toxic exposure. Mountain View Voice. November 22, 2002.
53. Risk management for trichloroethylene (TCE). US Environmental Protection Agency. www.epa.gov/assessing-and-managing-chemicals-under-tsca/risk-management-trichloroethylene-tce. Updated December 14, 2017. Accessed November 16, 2018; ToxFAQs for trichloroethylene (TCE). Agency for Toxic Substances & Disease Registry. Toxic Substances Portal. www.atsdr.cdc.gov/toxfaqs/tf.asp?id=172&tid=30. Updated November 4, 2016. Accessed March 14, 2019; DeBolt D. TCE causes cancer, other health problems, EPA says. Mountain View Voice. October 7, 2011.
54. Goldman SM, Quinlan PJ, Ross GW, et al. Solvent exposures and Parkinson disease risk in twins. Annals of Neurology. 2012;71(6):776–784; Bowdler N. Study links Parkinson’s disease to industrial solvent. BBC News. November 14, 2011.
55. Superfund: National Priorities List. US Environmental Protection Agency. www.epa.gov/superfund/superfund-national-priorities-list-npl. Updated June 4, 2018. Accessed January 9, 2019.
56. Trichloroehtylene (TCE). Algona/Auburn Public Awareness Coalition. www.wa-apac.org/questions-from-the-community-factsheets/trichloroethylene-tce/. Accessed August 10, 2018.
57. Record of decision: Modock Road Springs/DLS Sand and Gravel, Inc. Site, Town of Victor, Ontario County, New York, Site Number 8-35-013. New York State Department of Environmental Conservation. January 2010. www.dec.ny.gov/docs/remediation_hudson_pdf/835013rod.pdf. Accessed March 29, 2019.
58. Ibid.; Modock Springs. Town of Victor, New York. www.victorny.org/260/Modock-Springs. Accessed March 29, 2019.
59. Youngman J, Maslanik M. Cancer study of Victor’s “plume” inconclusive. Daily Messenger. October 16, 2009.
60. Barringer F. Exposed to solvent, worker faces hurdles. New York Times. January 24, 2009; Trichloroethylene. Wikipedia. https://en.wikipedia.org/wiki/Trichloroethylene. Updated May 28, 2018. Accessed March 31, 2019; C2 chlorinated solvents. IHS Markit. October 2017. https://ihsmarkit.com/products/c2-chlorinated-chemical-economics-handbook.html. Accessed March 26, 2019.
61. Risk management for trichloroethylene (TCE). US Environmental Protection Agency. www.epa.gov/assessing-and-managing-chemicals-under-tsca/risk-management-trichloroethylene-tce. Updated December 14, 2017. Accessed November 16, 2018; Integrated Risk Information System: trichloroethylene. US Environmental Protection Agency. https://cfpub.epa.gov/ncea/iris2/chemicalLanding.cfm?substance_nmbr=199. Updated July 28, 2017. Accessed March 28, 2019; Public health statement for trichloroethylene. Agency for Toxic Substances & Disease Registry. Toxic Substances Portal. www.atsdr.cdc.gov/phs/phs.asp?id=171&tid=30. Accessed March 29, 2019.
62. Risk management for trichloroethylene (TCE). US Environmental Protection Agency. www.epa.gov/assessing-and-managing-chemicals-under-tsca/risk-management-trichloroethylene-tce. Updated December 14, 2017. Accessed November 16, 2018.
63. Franklin K. Industry urges EPA to put the brakes on TCE ban. Chemical Watch. 2017. https://chemicalwatch.com/55210/industry-urges-epa-to-put-the-brakes-on-tce-ban. Updated 2018. Accessed March 31, 2019.
64. Ibid.
65. Ibid.
66. Kaplan S. In reversal, chemicals are cleared for use. New York Times. December 20, 2017:A16.
67. Ebbs S. Senators, families urge EPA to take stronger action on toxic chemicals. ABCNews. August 1, 2018. https://abcnews.go.com/Politics/senators-families-urge-epa-stronger-action-toxic-chemicals/story?id=56974123. Accessed December 6, 2018.
68. Hill AB. The environment and disease: association or causation? Proceedings of the Royal Society of Medicine. 1965;58(5):295–300.
69. GBD 2016 Parkinson’s Disease Collaborators. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology. 2018;17(11):939–953.
70. Hofman A, Stricker BH, Ikram MA, Koudstaal PJ, Darweesh SKL. Trends in the incidence of Parkinson disease in the general population: the Rotterdam Study. American Journal of Epidemiology. 2016;183(11):1018–1026.
71. Wesseling C, De Joode BVW, Ruepert C, et al. Paraquat in developing countries. International Journal of Occupational and Environmental Health. 2001;7(4):275–286.
72. Greve PA, Van Zoonen P. Organochlorine pesticides and PCBs in tissues from Dutch citizens (1968–1986). International Journal of Environmental Analytical Chemistry. 1990;38(2):265–277.
73. Report on Carcinogens Background Document for Trichloroethylene. National Toxicology Program; December 13–14, 2000.
74. Ritz B, Lee P-C, Hansen J, et al. Traffic-related air pollution and Parkinson’s disease in Denmark: a case-control study. Environmental Health Perspectives. 2016;124(3):351–356; Finkelstein MM, Jerrett M. A study of the relationships between Parkinson’s disease and markers of traffic-derived and environmental manganese air pollution in two Canadian cities. Environmental Research. 2007;104(3):420–432; Block ML, Calderón-Garcidueñas L. Air pollution: mechanisms of neuroinflammation and CNS disease. Trends in Neurosciences. 2009;32(9):506–516; Netherlands—air pollution country fact sheet 2018. European Environment Agency. www.eea.europa.eu/themes/air/country-fact-sheets/netherlands. Accessed March 29, 2019.
75. Netherlands—air pollution country fact sheet 2018. European Environment Agency. www.eea.europa.eu/themes/air/country-fact-sheets/netherlands. Accessed March 29, 2019.
1. Almendrala A. Muhammad Ali’s greatest fight was against Parkinson’s disease. Huffington Post. June 6, 2016. www.huffpost.com/entry/one-of-muhammad-alis-greatest-legacies-is-his-fight-for-people-with-parkinsons-disease_n_5755bfe8e4b0eb20fa0ea112. Accessed October 15, 2018.
2. Geiger LE. Etiologies of parkinsonism. Bulletin of the Los Angeles Neurological Society. 1975;40(4):160–194.
3. Bower JH, Maraganore DM, Peterson BJ, McDonnell SK, Ahlskog JE, Rocca WA. Head trauma preceding PD: a case-control study. Neurology. 2003;60(10):1610–1615; Siavash J, Mahyar E, Farhad A, Ali S. Head injury and risk of Parkinson disease: a systematic review and meta-analysis. Movement Disorders. 2013;28(9):1222–1229; Harris MA, Shen H, Marion SA, Tsui JK, Teschke K. Head injuries and Parkinson’s disease in a case-control study. Occupational and Environmental Medicine. 2013;70(12):839–844.
4. Goldman SM, Tanner CM, Oakes D, Bhudhikanok GS, Gupta A, Langston JW. Head injury and Parkinson’s disease risk in twins. Annals of Neurology. 2006;60(1):65–72.
5. Ibid.
6. Crane PK, Gibbons LE, Dams-O’Connor K, et al. Association of traumatic brain injury with late-life neurodegenerative conditions and neuropathologic findings. JAMA Neurology. 2016;73(9):1062–1069; Uryu K, Chen X-H, Martinez D, et al. Multiple proteins implicated in neurodegenerative diseases accumulate in axons after brain trauma in humans. Experimental Neurology. 2007;208(2):185–192.
7. Lee P-C, Bordelon Y, Bronstein J, Ritz B. Traumatic brain injury, paraquat exposure, and their relationship to Parkinson disease. Neurology. 2012;79(20):2061–2066.
8. Omalu BI, DeKosky ST, Minster RL, Kamboh MI, Hamilton RL, Wecht CH. Chronic traumatic encephalopathy in a National Football League player. Neurosurgery. 2005;57(1):128–134; Mez J, Daneshvar DH, Kiernan PT, et al. Clinicopathological evaluation of chronic traumatic encephalopathy in players of American football. JAMA. 2017;318(4):360–370; Lehman EJ, Hein MJ, Baron SL, Gersic CM. Neurodegenerative causes of death among retired National Football League players. Neurology. 2012;79(19):1970–1974; Kubilus CA, Nowinski CJ, Budson AE, et al. Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. Journal of Neuropathology & Experimental Neurology. 2009;68(7):709–735.
9. Lehman EJ, Hein MJ, Baron SL, Gersic CM. Neurodegenerative causes of death among retired National Football League players. Neurology. 2012;79(19):1970–1974.
10. Mez J, Daneshvar DH, Kiernan PT, et al. Clinicopathological evaluation of chronic traumatic encephalopathy in players of American football. JAMA. 2017;318(4):360–370.
11. Ibid.
12. Borland C. I quit the NFL but have hope for football’s future. Huffington Post. February 1, 2018. www.huffingtonpost.com/entry/opinion-borland-nfl-cte_us_5a72024de4b03699143ec7a3. Accessed October 15, 2018.
13. Mez J, Daneshvar DH, Kiernan PT, et al. Clinicopathological evaluation of chronic traumatic encephalopathy in players of American football. JAMA. 2017;318(4):360–370.
14. Borland C. I quit the NFL but have hope for football’s future. Huffington Post. February 1, 2018. www.huffingtonpost.com/entry/opinion-borland-nfl-cte_us_5a72024de4b03699143ec7a3. Accessed October 15, 2018.
15. Ezell L. Timeline: the NFL’s concussion crisis. PBS Frontline. October 8, 2013. www.pbs.org/wgbh/pages/frontline/sports/league-of-denial/timeline-the-nfls-concussion-crisis/#2001. Accessed October 15, 2018.
16. Belson K. Brain trauma to affect one in three players, N.F.L. agrees. New York Times. September 13, 2014:A1.
17. Concussions in American football. Wikipedia. https://en.wikipedia.org/wiki/Concussions_in_American_football#Federal_NFL_concussion_litigation. Accessed October 15, 2018.
18. Hruby P. Startling jump in NFL player claims for Parkinson’s and ALS pushes payout projections past 65-year total in 18 months. Los Angeles Times. August 8, 2018.
19. Ibid.
20. Press A. Forrest Gregg fighting Parkinson’s. ESPN. November 16, 2011. www.espn.com/nfl/story/_/id/7242215/forrest-gregg-says-fighting-parkinsons. Accessed December 7, 2018.
21. Ibid.
22. ESPN News Services. Hall of Fame lineman Forrest Gregg dies at 85. ESPN. April 12, 2019. www.espn.com/nfl/story/_/id/26505006/hall-fame-lineman-forrest-gregg-dies-85. Accessed May 19, 2019.
23. Kontos AP, Elbin RJ, Fazio-Sumrock VC, et al. Incidence of sports-related concussion among youth football players aged 8–12 years. Journal of Pediatrics. 2013;163(3):717–720.
24. Marar M, McIlvain NM, Fields SK, Comstock RD. Epidemiology of concussions among United States high school athletes in 20 sports. American Journal of Sports Medicine. 2012;40(4):747–755; Gessel LM, Fields SK, Collins CL, Dick RW, Comstock RD. Concussions among United States high school and collegiate athletes. Journal of Athletic Training. 2007;42(4):495–503; Dompier TP, Kerr ZY, Marshall SW, et al. Incidence of concussion during practice and games in youth, high school, and collegiate American football players. JAMA Pediatrics. 2015;169(7):659–665.
25. McCrea M, Hammeke T, Olsen G, Leo P, Guskiewicz K. Unreported concussion in high school football players: implications for prevention. Clinical Journal of Sport Medicine. 2004;14(1):13–17.
26. Kroshus E, Garnett B, Hawrilenko M, Baugh CM, Calzo JP. Concussion under-reporting and pressure from coaches, teammates, fans, and parents. Social Science & Medicine. 2015;134:66–75.
27. Marar M, McIlvain NM, Fields SK, Comstock RD. Epidemiology of concussions among United States high school athletes in 20 sports. American Journal of Sports Medicine. 2012;40(4):747–755.
28. Ibid.
29. Ibid.
30. DoD worldwide numbers for TBI. Defense and Veterans Brain Injury Center. https://dvbic.dcoe.mil/dod-worldwide-numbers-tbi. Accessed March 26, 2019.
31. Gardner RC, Byers AL, Barnes DE, Li Y, Boscardin J, Yaffe K. Mild TBI and risk of Parkinson disease: a chronic effects of neurotrauma consortium study. Neurology. 2018;90(20):e1771–e1779.
32. DoD worldwide numbers for TBI. Defense and Veterans Brain Injury Center. https://dvbic.dcoe.mil/dod-worldwide-numbers-tbi. Accessed March 26, 2019.
33. DoD worldwide numbers for TBI. Defense and Veterans Brain Injury Center. https://dvbic.dcoe.mil/dod-worldwide-numbers-tbi. Accessed March 26, 2019.
34. Gardner RC, Byers AL, Barnes DE, Li Y, Boscardin J, Yaffe K. Mild TBI and risk of Parkinson disease: a chronic effects of neurotrauma consortium study. Neurology. 2018;90(20):e1771–e1779.
35. Ibid.
36. Williams Gowers (neurologist). Wikipedia. https://en.wikipedia.org/wiki/William_Gowers_(neurologist). Accessed March 14, 2019.
37. Ibid.; Gowers W. Paralysis agitans. Macmillan; 1899.
38. McCarrick K. Changing course: Jimmy Choi’s story. FoxFeed Blog. May 29, 2018. www.michaeljfox.org/news/changing-course-jimmy-chois-story. Accessed June 27, 2019.
39. Boiles A. WATCH NOW: athlete with Parkinson’s Jimmy Choi becomes an American ninja warrior. Foxfeed Blog. July 4, 2017. www.michaeljfox.org/news/watch-now-athlete-parkinsons-jimmy-choi-becomes-american-ninja-warrior. Accessed June 27, 2019.
40. McCarrick K. Changing course: Jimmy Choi’s story. Foxfeed Blog. May 29, 2018. www.michaeljfox.org/news/changing-course-jimmy-chois-story. Accessed June 27, 2019.
41. Terraso D. Professor pedals across Iowa to test benefits on Parkinson’s disease. Georgia Institute of Technology News Center. July 21, 2004. www.news.gatech.edu/2004/07/21/professor-pedals-across-iowa-test-benefits-parkinsons-disease. Accessed March 14, 2019.
42. Bridges A. Pedaling away from Parkinson’s. Santa Barbara Independent. August 11, 2014.
43. Reynolds G. What Parkinson’s teaches us about the brain. Well (blog), New York Times. October 12, 2011. https://well.blogs.nytimes.com/2011/10/12/what-parkinsons-teaches-us-about-the-brain. Accessed June 27, 2019.
44. Pedaling for Parkinson’s. www.pedalingforparkinsons.org. Accessed March 14, 2019.
45. Bridges A. Pedaling away from Parkinson’s. Santa Barbara Independent. August 11, 2014; Pedaling for Parkinson’s. www.pedalingforparkinsons.org. Accessed March 14, 2019.
46. Ridgel AL, Vitek JL, Alberts JL. Forced, not voluntary, exercise improves motor function in Parkinson’s disease patients. Neurorehabilitation and Neural Repair. 2009;23(6):600–608.
47. Alberts JL, Linder SM, Penko AL, Lowe MJ, Phillips M. It is not about the bike, it is about the pedaling: forced exercise and Parkinson’s disease. Exercise and Sport Sciences Reviews. 2011;39(4):177–186.
48. Ibid.
49. Goodwin VA, Richards SH, Taylor RS, Taylor AH, Campbell JL. The effectiveness of exercise interventions for people with Parkinson’s disease: a systematic review and meta-analysis. Movement Disorders. 2008;23(5):631–640.
50. Müller J, Myers J. Association between physical fitness, cardiovascular risk factors, and Parkinson’s disease. European Journal of Preventive Cardiology. 2018;25(13):1409–1415.
51. Fang X, Han D, Cheng Q, et al. Association of levels of physical activity with risk of Parkinson disease: a systematic review and meta-analysis. JAMA Network Open. 2018;1(5):e182421; Thacker EL, Chen H, Patel AV, et al. Recreational physical activity and risk of Parkinson’s disease. Movement Disorders. 2008;23(1):69–74.
52. Ascherio A, Schwarzschild MA. The epidemiology of Parkinson’s disease: risk factors and prevention. Lancet Neurology. 2016;15(12):1257–1272; Sun Q, Townsend MK, Okereke OI, Franco OH, Hu FB, Grodstein F. Physical activity at midlife in relation to successful survival in women at age 70 years or older. Archives of Internal Medicine. 2010;170(2):194–201; Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE. Exercise capacity and mortality among men referred for exercise testing. New England Journal of Medicine. 2002;346(11):793–801; Gebel K, Ding D, Chey T, Stamatakis E, Brown WJ, Bauman AE. Effect of moderate to vigorous physical activity on all-cause mortality in middle-aged and older Australians. JAMA Internal Medicine. 2015;175(6):970–977.
53. Fang X, Han D, Cheng Q, et al. Association of levels of physical activity with risk of Parkinson disease: a systematic review and meta-analysis. JAMA Network Open. 2018;1(5):e182421; Metabolic equivalent. Wikipedia. https://en.wikipedia.org/wiki/Metabolic_equivalent. Accessed October 15, 2018.
54. Serra-Majem L, Roman B, Estruch R. Scientific evidence of interventions using the Mediterranean diet: a systemic review. Nutritional Review. 2006;64:S27–S47; Casini A, Gensini GF, Abbate R, Sofi F. Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. American Journal of Clinical Nutrition. 2010;92(5):1189–1196.
55. Casini A, Gensini GF, Abbate R, Sofi F. Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. American Journal of Clinical Nutrition. 2010;92(5):1189–1196.
56. Alcalay RN, Gu Y, Mejia-Santana H, Cote L, Marder KS, Scarmeas N. The association between Mediterranean diet adherence and Parkinson’s disease. Movement Disorders. 2012;27(6):771–774.
57. Gao X, Chen H, Fung TT, et al. Prospective study of dietary pattern and risk of Parkinson disease. American Journal of Clinical Nutrition. 2007;86(5):1486–1494.
58. Alcalay RN, Gu Y, Mejia-Santana H, Cote L, Marder KS, Scarmeas N. The association between Mediterranean diet adherence and Parkinson’s disease. Movement Disorders. 2012;27(6):771–774; Sofi F, Cesari F, Abbate R, Gensini GF, Casini A. Adherence to Mediterranean diet and health status: meta-analysis. BMJ. 2008;337.
59. Alcalay RN, Gu Y, Mejia-Santana H, Cote L, Marder KS, Scarmeas N. The association between Mediterranean diet adherence and Parkinson’s disease. Movement Disorders. 2012;27(6):771–774.
60. Gao X, Chen H, Fung TT, et al. Prospective study of dietary pattern and risk of Parkinson disease. American Journal of Clinical Nutrition. 2007;86(5):1486–1494.
61. Jin H, Kanthasamy A, Ghosh A, Anantharam V, Kalyanaraman B, Kanthasamy AG. Mitochondria-targeted antioxidants for treatment of Parkinson’s disease: preclinical and clinical outcomes. Biochimica et Biophysica Acta. 2014;1842(8):1282–1294.
62. Ross G, Abbott RD, Petrovitch H, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA. 2000;283(20):2674–2679; Paganini-Hill A. Risk factors for Parkinson’s disease: the leisure world cohort study. Neuroepidemiology. 2001;20(2):118–124; Ascherio A, Zhang SM, Hernan MA, et al. Prospective study of caffeine consumption and risk of Parkinson’s disease in men and women. Annals of Neurology. 2001;50(1):56–63; Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease. Annals of Neurology. 2002;52(3):276–284; Tan LC, Koh WP, Yuan JM, et al. Differential effects of black versus green tea on risk of Parkinson’s disease in the Singapore Chinese Health Study. American Journal of Epidemiology. 2008;167(5):553–560; Liu R, Guo X, Park Y, et al. Caffeine intake, smoking, and risk of Parkinson disease in men and women. American Journal of Epidemiology. 2012;175(11):1200–1207.
63. Ross G, Abbott RD, Petrovitch H, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA. 2000;283(20):2674–2679.
64. Ibid.; Munoz DG, Fujioka S. Caffeine and Parkinson disease: a possible diagnostic and pathogenic breakthrough. Neurology. 2018;90(5):205–206.
65. Ascherio A, Zhang SM, Hernan MA, et al. Prospective study of caffeine consumption and risk of Parkinson’s disease in men and women. Annals of Neurology. 2001;50(1):56–63.
66. Munoz DG, Fujioka S. Caffeine and Parkinson disease: A possible diagnostic and pathogenic breakthrough. Neurology. 2018;90(5):205–206; Schwarzschild MA, Chen JF, Ascherio A. Caffeinated clues and the promise of adenosine A(2A) antagonists in PD. Neurology. 2002;58(8):1154–1160.
67. Postuma RB, Anang J, Pelletier A, et al. Caffeine as symptomatic treatment for Parkinson disease (Café-PD): a randomized trial. Neurology. 2017;89(17):1795–1803.
68. Palacios N, Gao X, McCullough ML, et al. Caffeine and risk of Parkinson’s disease in a large cohort of men and women. Movement Disorders. 2012;27(10):1276–1282.
69. Wikoff D, Welsh BT, Henderson R, et al. Systematic review of the potential adverse effects of caffeine consumption in healthy adults, pregnant women, adolescents, and children. Food and Chemical Toxicology. 2017;109:585–648.
1. Boston JG. JCC Greater Boston—building a new beginning [video file]. YouTube. March 23, 2018. www.youtube.com/watch?v=unw3Ue2DWME.
2. Lagro-Janssen ALM, van den Heuvel EAJ, Bor HH, et al. Prodromal symptoms and early detection of Parkinson’s disease in general practice: a nested case-control study. Family Practice. 2014;31(4):373–378; Gonera EG, Hof MVt, Berger HJC, van Weel C, Horstink MWIM. Symptoms and duration of the prodromal phase in Parkinson’s disease. Movement Disorders. 1997;12(6):871–876.
3. Osler W, Sir. The Principles and Practice of Medicine. D. Appleton and Company; 1892.
4. Taylor KSM, Counsell CE, Harris CE, Gordon JC. Screening for undiagnosed parkinsonism in people aged 65 years and over in the community. Parkinsonism & Related Disorders. 2006;12(2):79–85.
5. Nicoletti A, Sofia V, Bartoloni A, et al. Prevalence of Parkinson’s disease: a door-to-door survey in rural Bolivia. Parkinsonism & Related Disorders. 2003;10(1):19–21.
6. Kis B, Schrag A, Ben-Shlomo Y, et al. Novel three-stage ascertainment method: prevalence of PD and parkinsonism in South Tyrol, Italy. Neurology. 2002;58(12):1820–1825.
7. Muangpaisan W, Hori H, Brayne C. Systematic review of the prevalence and incidence of Parkinson’s disease in Asia. Journal of Epidemiology. 2009;19(6):281–293.
8. Schoenberg BS, Anderson DW, Haerer AF. Prevalence of Parkinson’s disease in the biracial population of Copiah County, Mississippi. Neurology. 1985;35(6):841–845.
9. Safarpour D, Thibault DP, DeSanto CL, et al. Nursing home and end-of-life care in Parkinson disease. Neurology. 2015;85(5):413–419.
10. Buchanan RJ, Wang S, Huang C, Simpson P, Manyam BV. Analyses of nursing home residents with Parkinson’s disease using the minimum data set. Parkinsonism & Related Disorders. 2002;8(5):369–380.
11. Weerkamp NJ, Zuidema SU, Tissingh G, et al. Motor profile and drug treatment of nursing home residents with Parkinson’s disease. Journal of the American Geriatrics Society. 2012;60(12):2277–2282.
12. Safarpour D, Thibault DP, DeSanto CL, et al. Nursing home and end-of-life care in Parkinson disease. Neurology. 2015;85(5):413–419.
13. Weerkamp NJ, Tissingh G, Poels PJE, et al. Diagnostic accuracy of Parkinson’s disease and atypical parkinsonism in nursing homes. Parkinsonism & Related Disorders. 2014;20(11):1157–1160.
14. Willis AW, Schootman M, Evanoff BA, Perlmutter JS, Racette BA. Neurologist care in Parkinson disease: a utilization, outcomes, and survival study. Neurology. 2011;77(9):851–857.
15. Ibid.
16. Ibid.
17. Papanicolas I, Woskie LR, Jha AK. Health care spending in the United States and other high-income countries. JAMA. 2018;319(10):1024–1039; Dahodwala N, Xie M, Noll E, Siderowf A, Mandell DS. Treatment disparities in Parkinson’s disease. Annals of Neurology. 2009;66(2):142–145.
18. Willis AW, Schootman M, Evanoff BA, Perlmutter JS, Racette BA. Neurologist care in Parkinson disease: a utilization, outcomes, and survival study. Neurology. 2011;77(9):851–857.
19. Willis AW, Schootman M, Kung N, Wang X-Y, Perlmutter JS, Racette BA. Disparities in deep brain stimulation surgery among insured elders with Parkinson disease. Neurology. 2014;82(2):163–171.
20. Willis AW, Schootman M, Tran R, et al. Neurologist-associated reduction in PD-related hospitalizations and health care expenditures. Neurology. 2012;79(17):1774–1780.
21. Gage H, Hendricks A, Zhang S, Kazis L. The relative health related quality of life of veterans with Parkinson’s disease. Journal of Neurology, Neurosurgery, and Psychiatry. 2003;74(2):163–169.
22. Seidman C. Caring for wife with dementia leads husband to contemplate suicide. Sarasota Herald-Tribune. July 12, 2018; Opinion.
23. Caregiving in the U.S. 2015—executive summary. National Alliance for Caregiving. June 2015. www.caregiving.org/wp-content/uploads/2015/05/2015_CaregivingintheUS_Executive-Summary-June-4_WEB.pdf. Accessed June 27, 2019.
24. Schrag A, Hovris A, Morley D, Quinn N, Jahanshahi M. Caregiver-burden in Parkinson’s disease is closely associated with psychiatric symptoms, falls, and disability. Parkinsonism & Related Disorders. 2006;12(1):35–41.
25. Schulz R, Beach SR. Caregiving as a risk factor for mortality: the caregiver health effects study. JAMA. 1999;282(23):2215–2219.
26. Ahlskog JE. Beating a dead horse: dopamine and Parkinson disease. Neurology. 2007;69(17):1701–1711.
27. Nijkrake MJ, Keus SHJ, Overeem S, et al. The ParkinsonNet concept: development, implementation and initial experience. Movement Disorders. 2010;25(7):823–829; Bloem BR, Rompen L, de Vries NM, Klink A, Munneke M, Jeurissen P. ParkinsonNet: A low-cost health care innovation with a systems approach from the Netherlands. Health Affairs. 2017;36:1987–1996; Munneke M, Nijkrake MJ, Keus SHJ, et al. Efficacy of community-based physiotherapy networks for patients with Parkinson’s disease: a cluster-randomised trial. Lancet Neurology. 2010;9(1):46–54; Wensing M, van der Eijk M, Koetsenruijter J, Bloem BR, Munneke M, Faber M. Connectedness of healthcare professionals involved in the treatment of patients with Parkinson’s disease: a social networks study. Implementation Science. 2011;6(1):67; Keus SHJ, Oude Nijhuis LB, Nijkrake MJ, Bloem BR, Munneke M. Improving community healthcare for patients with Parkinson’s disease: the Dutch model. Journal of Parkinson’s Disease. 2012;2012:543426; van der Ejik M, Faber MJ, Aarts JW, Kremer JA, Munneke M, Bloem BR. Using online health communities to deliver patient-centered care to people with chronic conditions. Journal of Medical Internet Research. 2013;15(6):e115; Sturkenboom IHWM, Graff MJL, Hendriks JCM, et al. Efficacy of occupational therapy for patients with Parkinson’s disease: a randomised controlled trial. Lancet Neurology. 2014;13(6):557–566; Bloem BR, Munneke M. Revolutionising management of chronic disease: the ParkinsonNet approach. BMJ. 2014;348:g1838; Ypinga JHL, de Vries NM, Boonen LHHM, et al. Effectiveness and costs of specialised physiotherapy given via ParkinsonNet: a retrospective analysis of medical claims data. Lancet Neurology. 2018;17(2):153–161.
28. Bloem BR, Rompen L, de Vries NM, Klink A, Munneke M, Jeurissen P. ParkinsonNet: a low-cost health care innovation with a systems approach from the Netherlands. Health Affairs. 2017;36:1987–1996.
29. Ibid.
30. Dorsey ER, Glidden AM, Holloway MR, Birbeck GL, Schwamm LH. Teleneurology and mobile technologies: the future of neurological care. Nature Reviews Neurology. 2018;14:285–297.
31. Arora S, Thornton K, Murata G, et al. Outcomes of Treatment for Hepatitis C Virus Infection by Primary Care Providers. New England Journal of Medicine. 2011;364(23):2199–2207.
32. Arora S. Project ECHO: the evidence is catching up with the enthusiasm. Health Affairs Blog. January 13, 2017. www.healthaffairs.org/do/10.1377/hblog20170113.058331/full. Accessed June 27, 2019; Catic AG, Mattison MLP, Bakaev I, Morgan M, Monti SM, Lipsitz L. ECHO-AGE: an innovative model of geriatric care for long-term care residents with dementia and behavioral issues. Journal of the American Medical Directors Association. 2014;15(12):938–942; Project ECHO: a revolution in medical education and care delivery. University of New Mexico. https://echo.unm.edu. Accessed November 11, 2018.
33. Dorsey ER, Glidden AM, Holloway MR, Birbeck GL, Schwamm LH. Teleneurology and mobile technologies: the future of neurological care. Nature Reviews Neurology. 2018;14:285–297.
34. Meyer GS, Gibbons RV. House calls to the elderly—a vanishing practice among physicians. New England Journal of Medicine. 1997;337(25):1815–1820.
35. Ibid.
36. Sairenji T, Jetty A, Peterson LE. Shifting patterns of physician home visits. Journal of Primary Care & Community Health. 2015;7(2):71–75.
37. Fleisher J, Barbosa W, Sweeney MM, et al. Interdisciplinary home visits for individuals with advanced Parkinson’s disease and related disorders. Journal of the American Geriatrics Society. 2018;66(6):1226–1232.
38. Ibid.
39. Hack N, Akbar U, Monari, EH, et al. Person-centered care in the home setting for Parkinson’s disease: operation house call quality of care pilot study. Journal of Parkinson’s Disease. 2015;2015;639494. doi:10.1155/2015/639494. www.ncbi.nlm.nih.gov/pmc/articles/PMC4452493.
40. Beck CA, Beran DB, Biglan KM, et al. National randomized controlled trial of virtual house calls for Parkinson disease. Neurology. 2017;89(11):1152–1161; Shah SP, Glenn GL, Hummel EM, et al. Caregiver tele-support group for Parkinson’s disease: a pilot study. Geriatric Nursing. 2015;36(3):207–211; Korn RE, Shukla AW, Katz M, et al. Virtual visits for Parkinson disease. Neurology: Clinical Practice. 2017;7(4):283–295; Venkataraman V, Donohue SJ, Biglan KM, Wicks P, Dorsey ER. Virtual visits for Parkinson disease. Neurology: Clinical Practice. 2014;4(2):146–152.
41. Beck CA, Beran DB, Biglan KM, et al. National randomized controlled trial of virtual house calls for Parkinson disease. Neurology. 2017;89(11):1152–1161; Dorsey ER, Venkataraman V, Grana MJ, et al. Randomized controlled clinical trial of “virtual house calls” for Parkinson disease. JAMA Neurology. 2013;70(5):565–570; Heikkilä VM, Turkka J, Korpelainen J, Kallanranta T, Summala H. Decreased driving ability in people with Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry. 1998;64(3):325–330.
42. Beck CA, Beran DB, Biglan KM, et al. National randomized controlled trial of virtual house calls for Parkinson disease. Neurology. 2017;89(11):1152–1161; Dorsey ER, Venkataraman V, Grana MJ, et al. Randomized controlled clinical trial of “virtual house calls” for Parkinson disease. JAMA Neurology. 2013;70(5):565–570; Heikkilä VM, Turkka J, Korpelainen J, Kallanranta T, Summala H. Decreased driving ability in people with Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry. 1998;64(3):325–330.
43. Beck CA, Beran DB, Biglan KM, et al. National randomized controlled trial of virtual house calls for Parkinson disease. Neurology. 2017;89(11):1152–1161.
44. Hubble JP. Interactive video conferencing and Parkinson’s disease. Kansas Medicine. 1992;93(12):351–352.
45. Ibid.
46. Achey M, Aldred JL, Aljehani N, et al. The past, present, and future of telemedicine for Parkinson’s disease. Movement Disorders 2014;29(7):871–883. https://onlinelibrary.wiley.com/doi/full/10.1002/mds.25903.
47. Silva de Lima AL, Hahn T, Evers LJW, et al. Feasibility of large-scale deployment of multiple wearable sensors in Parkinson’s disease. PLOS ONE. 2017;12(12):e0189161.
48. Lipsmeier F, Taylor KI, Kilchenmann T, et al. Evaluation of smartphone-based testing to generate exploratory outcome measures in a phase 1 Parkinson’s disease clinical trial. Movement Disorders. 2018;33(8):1287–1297.
49. Dorsey ER, Glidden AM, Holloway MR, et al. Teleneurology and mobile technologies: the future of neurological care. Nat Rev Neurol 2018;14(5):285–297. www.ncbi.nlm.nih.gov/pubmed/29623949.
50. Sharma S, Padma MV, Bhardwaj A, Sharma A, Sawal N, Thakur S. Telestroke in resource-poor developing country model. Neurology India. 2016;64(5):934–940; Corley J. Telestroke: India’s solution to a public health-care crisis. Lancet Neurology. 2018;17(2):115–116.
51. Topol E. The Patient Will See You Now: The Future of Medicine Is in Your Hands. Rpt. ed. Basic Books; 2016.
52. Daschle T, Dorsey ER. The return of the house call. Annals of Internal Medicine. 2015;162(8):587–588.
53. Gornick ME, Warren JL, Eggers PW, et al. Thirty years of Medicare: impact on the covered population. Health Care Financing Review. 1996;18(2):179–237; Life expectancy for Social Security. Social Security Administration. www.ssa.gov/history/lifeexpect.html. Accessed November 10, 2018.
54. Thorpe KE, Ogden LL, Galactionova K. Chronic conditions account for rise in Medicare spending from 1987 to 2006. Health Affairs. 2010;29(4):718–724.
55. AARP. Baby boomer facts and figures. AARP Livable Communities. www.aarp.org/livable-communities/info-2014/livable-communities-facts-and-figures.html. Accessed January 5, 2019.
56. Dieleman JL, Baral R, Birger M, et al. US spending on personal health care and public health, 1996–2013. JAMA. 2016;316(24):2627–2646.
57. Ibid.
58. Dorsey ER, George BP, Leff B, Willis AW. The coming crisis: obtaining care for the growing burden of neurodegenerative conditions. Neurology. 2013;80(21):1989–1996.
59. Ibid.; Barnett ML, Wilcock A, McWilliams JM, et al. Two-year evaluation of mandatory bundled payments for joint replacement. New England Journal of Medicine. 2019;380(3):252–262; Silverman L, Walters D, Aasen E, Tainter R, Whittington J, Holter R. Chapter 7: the cost of a broken hip. KERA. 2017. http://stories.kera.org/the-broken-hip/the-cost-of-a-broken-hip. Accessed February 11, 2019.
60. Dorsey ER, Vlaanderen FP, Engelen LJ, et al. Moving Parkinson care to the home. Movement Disorders. 2016;31(9):1258–1262.
61. Ibid.; Gerlach OHH, Winogrodzka A, Weber WEJ. Clinical problems in the hospitalized Parkinson’s disease patient: systematic review. Movement Disorders. 2011;26(2):197–208; Aminoff MJ, Christine CW, Friedman JH, et al. Management of the hospitalized patient with Parkinson’s disease: current state of the field and need for guidelines. Parkinsonism & Related Disorders. 2011;17(3):139–145.
62. Ypinga JHL, de Vries NM, Boonen LHHM, et al. Effectiveness and costs of specialised physiotherapy given via ParkinsonNet: a retrospective analysis of medical claims data. Lancet Neurology. 2018;17(2):153–161.
63. Parkinson’s disease insight report. Wilmington Healthcare. https://wilmingtonhealthcare.com/what-we-do/nhs-service-improvement/parkinsons-disease-insight-report. Accessed May 19, 2019.
64. Allen NE, Schwarzel AK, Canning CG. Recurrent falls in Parkinson’s disease: a systematic review. Journal of Parkinson’s Disease. 2013;2013:906274.
65. Walker RW, Chaplin A, Hancock RL, Rutherford R, Gray WK. Hip fractures in people with idiopathic Parkinson’s disease: incidence and outcomes. Movement Disorders. 2013;28(3):334–340; Kalilani L, Asgharnejad M, Palokangas T, Durgin T. Comparing the incidence of falls/fractures in Parkinson’s disease patients in the US population. PLOS ONE. 2016;11(9):e0161689–e0161689.
66. Li F, Harmer P, Fitzgerald K, et al. Tai chi and postural stability in patients with Parkinson’s disease. New England Journal of Medicine. 2012;366(6):511–519; Ypinga JHL, de Vries NM, Boonen LHHM, et al. Effectiveness and costs of specialised physiotherapy given via ParkinsonNet: a retrospective analysis of medical claims data. Lancet Neurology. 2018;17(2):153–161; van der Marck MA, Klok MPC, Okun MS, Giladi N, Munneke M, Bloem BR. Consensus-based clinical practice recommendations for the examination and management of falls in patients with Parkinson’s disease. Parkinsonism & Related Disorders. 2014;20(4):360–369.
67. Florence CS, Bergen G, Atherly A, Burns E, Stevens J, Drake C. Medical costs of fatal and nonfatal falls in older adults. Journal of the American Geriatrics Society. 2018;66(4):693–698.
68. Ibid.; Kaiser J. Final 2018 budget bill eases biomedical researchers’ policy worries. Science. March 22, 2018. American Association for the Advancement of Science. www.sciencemag.org/news/2018/03/final-2018-budget-bill-eases-biomedical-researchers-policy-worries. Accessed June 27, 2019.
69. Safarpour D, Thibault DP, DeSanto CL, et al. Nursing home and end-of-life care in Parkinson disease. Neurology. 2015;85(5):413–419.
70. Dorsey ER, George BP, Leff B, Willis AW. The coming crisis: obtaining care for the growing burden of neurodegenerative conditions. Neurology. 2013;80(21):1989–1996; Powell T. New hopes for dementia care. Wall Street Journal. April 11, 2019.
71. Dorsey ER, Topol EJ. State of telehealth. NEJM. 2016;375(2):154–161.
72. Wilkinson JR, Spindler M, Wood SM, et al. High patient satisfaction with telehealth in Parkinson disease: a randomized controlled study. Neurology Clinical Practice. 2016;6(3):241–251.
73. Telehealth services. In: Medicare Learning Network Booklet. Centers for Medicare & Medicaid Services; 2018.
74. Lacktman NM. Medicare payments for telehealth increased 28% in 2016: what you should know. Health Care Law Today. August 28, 2017. www.healthcarelawtoday.com/2017/08/28/medicare-payments-for-telehealth-increased-28-in-2016-what-you-should-know. Accessed November 2018.
75. Dorsey ER, George BP, Leff B, Willis AW. The coming crisis: obtaining care for the growing burden of neurodegenerative conditions. Neurology. 2013;80(21):1989–1996.
76. Rosenthal E. An American Sickness: How Healthcare Became Big Business and How You Can Take It Back. 1st ed. Penguin Press; 2017; Goodson JD. Unintended consequences of resource-based relative value scale reimbursement. JAMA. 2007;298(19):2308–2310.
77. Rosenthal E. An American Sickness: How Healthcare Became Big Business and How You Can Take It Back. 1st ed. Penguin Press; 2017.
78. Composition of the RVS Update Committee (RUC). American Medical Association. www.ama-assn.org/about/rvs-update-committee-ruc/composition-rvs-update-committee-ruc. Accessed March 26, 2019.
79. Ibid.
80. Ibid.; Struhal W, Sellner J, Lisnic V, Vécsei L, Müller E, Grisold W. Neurology residency training in Europe—the current situation. European Journal of Neurology. 2011;18(4):e36–e40.
81. Rosenthal E. An American Sickness: How Healthcare Became Big Business and How You Can Take It Back. 1st ed. Penguin Press; 2017.
82. Dorsey ER, George BP, Leff B, Willis AW. The coming crisis: obtaining care for the growing burden of neurodegenerative conditions. Neurology. 2013;80(21):1989–1996.
83. FAQs about the FDA Patient Representative Program. US Food and Drug Administration. www.fda.gov/ForPatients/ucm412529.htm. Updated May 12, 2018. Accessed March 19, 2019.
84. Dorsey ER, George BP, Leff B, Willis AW. The coming crisis: obtaining care for the growing burden of neurodegenerative conditions. Neurology. 2013;80(21):1989–1996; Rosenthal E. An American Sickness: How Healthcare Became Big Business and How You Can Take It Back. 1st ed. Penguin Press; 2017.
85. Historical evolution of FDA advisory committees. In: Rettig RA, Earley LE, Merill RA, eds. Institute of Medicine (US) Committee to Study the Use of Advisory Committees. National Academies Press; 1992.
1. FDA approved drugs for neurology. CenterWatch. www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology. Accessed November 29, 2018.
2. Ibid.
3. Prescribing information: INBRIJA. US Food and Drug Administration. December 2018. www.accessdata.fda.gov/drugsatfda_docs/label/2018/209184s000lbl.pdf.
4. Prescribing information: GOCOVRI. US Food and Drug Administration. August 2017. www.accessdata.fda.gov/drugsatfda_docs/label/2017/208944lbl.pdf.
5. Prescribing information: XADAGO. US Food and Drug Administration. March 2017. www.accessdata.fda.gov/drugsatfda_docs/label/2017/207145lbl.pdf.
6. Prescribing information: NUPLAZID. US Food and Drug Administration. April 2016. www.accessdata.fda.gov/drugsatfda_docs/label/2016/207318lbl.pdf.
7. Prescribing information: DUOPA. US Food and Drug Administration. September 2016. www.rxabbvie.com/pdf/duopa_pi.pdf.
8. Prescribing information: RYTARY. US Food and Drug Administration. January 2015. www.accessdata.fda.gov/drugsatfda_docs/label/2015/203312s000lbl.pdf.
9. Prescribing information: NORTHERA. US Food and Drug Administration. February 2014. www.accessdata.fda.gov/drugsatfda_docs/label/2014/203202lbl.pdf.
10. Novartis. Prescribing information: EXELON. US Food and Drug Administration. December 2018. www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/exelon.pdf.
11. Prescribing information: NEUPRO. US Food and Drug Administration. April 2012. www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s001lbl.pdf.
12. Prescribing information: APOKYN. US Food and Drug Administration. July 2014. www.accessdata.fda.gov/drugsatfda_docs/label/2014/021264s010lbl.pdf.
13. Novartis. Prescribing information: COMTAN. US Food and Drug Administration. September 28, 2010. www.accessdata.fda.gov/drugsatfda_docs/label/2010/020796s15lbl.pdf.
14. FDA approved drugs for neurology. CenterWatch. www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/10/neurology. Accessed November 29, 2018.
15. Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. New England Journal of Medicine. 2006;355(9):896–908.
16. Goetz CG. The history of Parkinson’s disease: early clinical descriptions and neurological therapies. Cold Spring Harbor Perspectives in Medicine. 2011;1(1):a008862; Wagle Shukla A, Okun MS. Surgical treatment of Parkinson’s disease: patients, targets, devices, and approaches. Neurotherapeutics. 2014;11(1):47–59.
17. Wagle Shukla A, Okun MS. Surgical treatment of Parkinson’s disease: patients, targets, devices, and approaches. Neurotherapeutics. 2014;11(1):47–59.
18. Alexander GE, Crutcher MD, DeLong MR. Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, “prefrontal” and “limbic” functions. In: Uylings HBM, Van Eden CG, De Bruin JPC, Corner MA, Feenstra MGP, eds. Progress in Brain Research. Vol 85. Elsevier; 1991:119–146; Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annual Review of Neuroscience. 1986;9(1):357–381.
19. Benabid AL, Pollak P, Louveau A, Henry S, de Rougemont J. Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. Stereotactic and Functional Neurosurgery. 1987;50(1–6):344–346.
20. Lozano AM, Eltahawy H. How does DBS work? Supplement to Clinical Neurophysiology. 2004;57:733–736.
21. Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. New England Journal of Medicine. 2006;355(9):896–908; Follett KA, Weaver FM, Stern M, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson’s disease. New England Journal of Medicine. 2010;362(22):2077–2091; Benabid AL, Chabardes S, Mitrofanis J, Pollak P. Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson’s disease. Lancet Neurology. 2009;8(1):67–81; Deep-Brain Stimulation for Parkinson’s Disease Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson’s disease. New England Journal of Medicine. 2001;345(13):956–963; Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA. 2009;301(1):63–73; Bronstein JM, Tagliati M, Alterman RL, et al. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Archives of Neurology. 2011;68(2):165.
22. Limousin P, Foltynie T. Long-term outcomes of deep brain stimulation in Parkinson disease. Nature Reviews Neurology. 2019;15(4):234–242.
23. Medtronic Activa Tremor Control System. US Food and Drug Administration. Premarket Approval (PMA). www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm?id=P960009. Updated March 25, 2019. Accessed March 29, 2019.
24. Rossi PJ, Giordano J, Okun MS. The problem of funding off-label deep brain stimulation: bait-and-switch tactics and the need for policy reform. JAMA Neurology. 2017;74(1):9–10; Abosch A, Timmermann L, Bartley S, et al. An international survey of deep brain stimulation procedural steps. Stereotactic and Functional Neurosurgery. 2013;91(1):1–11.
25. Eberle W, Penders J, Yazicioglu RF. Closing the loop for deep brain stimulation implants enables personalized healthcare for Parkinson’s disease patients. Paper presented at the 2011 Annual International Conference of the IEEE Engineering in Medicine and Biology Society, August 30–September 3, 2011; Patel S, Mancinelli C, Hughes R, Dalton A, Shih L, Bonato P. Optimizing deep brain stimulation settings using wearable sensing technology. Paper presented at the 2009 4th International IEEE/EMBS Conference on Neural Engineering, April 29–May 2, 2009.
26. Anidi C, O’Day JJ, Anderson RW, et al. Neuromodulation targets pathological not physiological beta bursts during gait in Parkinson’s disease. Neurobiology of Disease. 2018;120:107–117; Malekmohammadi M, Herron J, Velisar A, et al. Kinematic adaptive deep brain stimulation for resting tremor in Parkinson’s disease. Movement Disorders. 2016;31(3):426–428.
27. Parker KL, Kim Y, Alberico SL, Emmons EB, Narayanan NS. Optogenetic approaches to evaluate striatal function in animal models of Parkinson disease. Dialogues in Clinical Neuroscience. 2016;18(1):99–107.
28. Henderson R. The purple membrane from Halobacterium halobium. Annual Review of Biophysics and Bioengineering. 1977;6:87–109.
29. Ibid.
30. Parker KL, Kim Y, Alberico SL, Emmons EB, Narayanan NS. Optogenetic approaches to evaluate striatal function in animal models of Parkinson disease. Dialogues in Clinical Neuroscience. 2016;18(1):99–107.
31. Ibid.; Fenno L, Yizhar O, Deisseroth K. The development and application of optogenetics. Annual Review of Neuroscience. 2011;34(1):389–412.
32. Kravitz AV, Freeze BS, Parker PRL, et al. Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature. 2010;466(7306):622–626.
33. Ibid.
34. Ibid.
35. Alessi DR, Sammler E. LRRK2 kinase in Parkinson’s disease. Science. 2018;360(6384):36–37.
36. Ibid.
37. Denali Therapeutics announces positive clinical results from LRRK2 inhibitor program for Parkinson’s disease. Denali Therapeutics. August 1, 2018. http://investors.denalitherapeutics.com/news-releases/news-release-details/denali-therapeutics-announces-positive-clinical-results-lrrk2#ir-pages. Accessed November 29, 2018.
38. Denali Therapeutics announces first patient dosed in phase 1B study of DNL201 for Parkinson’s disease [press release]. Denali Therapeutics, December 10, 2018; Study to evaluate DNL201 in subjects with Parkinson’s disease. US National Library of Medicine: ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03710707. Updated March 28, 2019. Accessed March 29, 2019.
39. Tracking LRRK2-Parkinson’s progression for better trial design. Alzforum. March 23, 2018. www.alzforum.org/news/research-news/tracking-lrrk2-parkinsons-progression-better-trial-design. Accessed November 30, 2018.
40. Alessi DR, Sammler E. LRRK2 kinase in Parkinson’s disease. Science. 2018;360(6384):36–37.
41. Ibid.; Stott S. New LRRK2 results: game changer? Science of Parkinson’s. July 25, 2018. https://scienceofparkinsons.com/2018/07/25/lrrk-2. Accessed June 27, 2019; Di Maio R, Hoffman EK, Rocha EM, et al. LRRK2 activation in idiopathic Parkinson’s disease. Science Translational Medicine. 2018;10(451).
42. Di Maio R, Hoffman EK, Rocha EM, et al. LRRK2 activation in idiopathic Parkinson’s disease. Science Translational Medicine. 2018;10(451).
43. Goker-Alpan O, Schiffmann R, LaMarca ME, Nussbaum RL, McInerney-Leo A, Sidransky E. Parkinsonism among Gaucher disease carriers. Journal of Medical Genetics. 2004;41(12):937–940.
44. Klein C, Westenberger A. Genetics of Parkinson’s disease. Cold Spring Harbor Perspectives in Medicine. 2012;2(1):a008888; Alcalay RN, Caccappolo E, Mejia-Santana H, et al. Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the Consortium on Risk for Early-Onset Parkinson Disease study. Archives of Neurology. 2010;67(9):1116–1122.
45. Sidransky E, Lopez G. The link between the GBA gene and parkinsonism. Lancet Neurology. 2012;11(11):986–998.
46. Velayati A, Yu WH, Sidransky E. The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders. Current Neurology and Neuroscience Reports. 2010;10(3):190–198.
47. Konrad A. Meet the top VC in a race to find his own Parkinson’s cure. Forbes. April 18, 2017. www.forbes.com/sites/alexkonrad/2017/04/18/jonathan-silverstein-venturing-for-a-cure/#4d17b6ba50a3. Accessed June 27, 2019.
48. The Silverstein Foundation in the News. Silverstein Foundation for Parkinson’s with GBA. www.silversteinfoundation.org/in-the-news. Accessed March 29, 2019.
49. On the money. CNBC. August 19, 2017. https://archive.org/details/CNBC_20170819_093000_On_the_Money.
50. Silverstein Foundation for Parkinson’s with GBA. 2018. www.silversteinfoundation.org. Accessed November 30, 2018.
51. Konrad A. Meet the top VC in a race to find his own Parkinson’s cure. Forbes. April 18, 2017. www.forbes.com/sites/alexkonrad/2017/04/18/jonathan-silverstein-venturing-for-a-cure/#4d17b6ba50a3. Accessed June 27, 2019.
52. About Prevail. Prevail Therapeutics. www.prevailtherapeutics.com/about-prevail. Accessed November 30, 2018.
53. Silveira CRA, MacKinley J, Coleman K, et al. Ambroxol as a novel disease-modifying treatment for Parkinson’s disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial. BMC Neurology. 2019;19(1):20–20; McNeill A, Magalhaes J, Shen C, et al. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain. 2014;137(5):1481–1495; Sardi SP, Cedarbaum JM, Brundin P. Targeted therapies for Parkinson’s disease: from genetics to the clinic. Movement Disorders. 2018;33(5):684–696.
54. Kuhl MM. First trial begins testing drug in people with GBA mutation. FoxFeed Blog. February 14, 2017. www.michaeljfox.org/news/first-trial-begins-testing-drug-people-gba-mutation. Accessed June 27, 2019.
55. Ibid.; Sanofi initiates phase 2 clinical trial to evaluate therapy for genetic form of Parkinson’s disease [press release]. Business Wire. February 14, 2017. www.businesswire.com/news/home/20170214005771/en/Sanofi-Initiates-Phase-2-Clinical-Trial-Evaluate. Accessed June 27, 2019; A global study to assess the drug dynamics, efficacy, and safety of GZ/SAR402671 in Parkinson’s disease patients carrying a glucocerebrosidase (GBA) gene mutation (MOVES-PD). US National Library of Medicine: ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02906020. Updated March 14, 2019. Accessed March 29, 2019; Sardi SP, Viel C, Clarke J, et al. Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models. Proceedings of the National Academy of Sciences of the United States of America. 2017;114(10):2699–2704.
56. A global study to assess the drug dynamics, efficacy, and safety of GZ/SAR402671 in Parkinson’s disease patients carrying a glucocerebrosidase (GBA) gene mutation (MOVES-PD). US National Library of Medicine: ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02906020. Updated March 14, 2019. Accessed March 29, 2019.
57. Vision and mission. Parkinson’s Foundation. www.parkinson.org/about-us/vision-and-mission. Accessed March 29, 2019.
58. Parkinson’s Foundation announces new genetic initiative connecting Parkinson’s genetic data with clinical care [press release]. Parkinson’s Foundation. March 6, 2018. https://parkinson.org/about-us/Press-Room/Press-Releases/Parkinsons-Foundation-Announces-New-Genetic-Initiative-Connecting-Parkinsons-Genetic-Data-with-Clinical-Care. Accessed June 27, 2019.
59. Saunders-Pullman R, Mirelman A, Alcalay RN, et al. Progression in the LRRK2-associated Parkinson disease population. JAMA Neurology. 2018;75(3):312–319; Davis MY, Johnson CO, Leverenz JB, et al. Association of GBA mutations and the E326K polymorphism with motor and cognitive progression in Parkinson disease. JAMA Neurology. 2016;73(10):1217–1224; Genetics initiative. Parkinson’s Foundation. www.parkinson.org/research/genetics-initiative. Accessed March 29, 2019.
60. Rinaldo CR, Jr. Passive immunization against poliomyelitis: the Hammon gamma globulin field trials, 1951–1953. American Journal of Public Health. 2005;95(5):790–799.
61. Ibid.
62. Jankovic J, Goodman I, Safirstein B, et al. Safety and tolerability of multiple ascending doses of PRX002/RG7935, an anti-α-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial. JAMA Neurology. 2018;75(10):1206–1214.
63. Fletcher K. Trials to treatments: vaccines for Parkinson’s. Medium. November 19, 2018. https://medium.com/parkinsons-uk/vaccines-for-parkinsons-b09634c84017. Accessed May 20, 2019.
64. Jankovic J, Goodman I, Safirstein B, et al. Safety and tolerability of multiple ascending doses of PRX002/RG7935, an anti-α-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial. JAMA Neurology. 2018;75(10):1206–1214; Manfredsson FP, Tansey MG, Golde TE. Challenges in passive immunization strategies to treat Parkinson disease. JAMA Neurology. 2018;75(10):1180–1181.
65. AFFiRiS AG. AFFiRiS announces top line results of first-in-human clinical study using AFFITOPE PD03A, confirming immunogenicity and safety profile in Parkinson’s disease patients. Cision PR Newswire. June 7, 2017. www.prnewswire.com/news-releases/affiris-announces-top-line-results-of-first-in-human-clinical-study-using-affitope-pd03a-confirming-immunogenicity-and-safety-profile-in-parkinsons-disease-patients-627025511.html. Accessed June 27, 2019; Affitope PD03A. Parkinsons’s News Today. https://parkinsonsnewstoday.com/affitope-pd03a. Accessed March 29, 2019.
66. Kuhl MM. Vaccine for Parkinson’s reports positive results from boost study. FoxFeed Blog. September 7, 2016. www.michaeljfox.org/news/vaccine-parkinsons-reports-positive-results-boost-study. Accessed June 27, 2019.
67. Dieleman JL, Baral R, Birger M, et al. US spending on personal health care and public health, 1996–2013. JAMA. 2016;316(24):2627–2646.
68. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. New England Journal of Medicine. 2009;361(13):1268–1278; Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Archives of Neurology. 2002;59(12):1937–1943.
69. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. New England Journal of Medicine. 2009;361(13):1268–1278; Blandini F, Armentero MT, Fancellu R, Blaugrund E, Nappi G. Neuroprotective effect of rasagiline in a rodent model of Parkinson’s disease. Experimental Neurology. 2004;187(2):455–459.
70. Blandini F, Armentero MT, Fancellu R, Blaugrund E, Nappi G. Neuroprotective effect of rasagiline in a rodent model of Parkinson’s disease. Experimental Neurology. 2004;187(2):455–459.
71. 45 million Americans forego medications due to costs, new analysis shows—9 times the rate of the UK [press release]. Prescription Justice. February 6 2017. https://prescriptionjustice.org/press_release/45-million-americans-forego-medications-due-to-costs-new-analysis-shows-9-times-the-rate-of-the-uk. Accessed June 27, 2019.
72. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. Journal of Health Economics. 2016;47:20–33.
73. Adams CP, Brantner VV. Estimating the cost of new drug development: is it really $802 million? Health Affairs. 2006;25(2):420–428; Morgan S, Grootendorst P, Lexchin J, Cunningham C, Greyson D. The cost of drug development: a systematic review. Health Policy. 2011;100(1):4–17.
74. Adams CP, Brantner VV. Estimating the cost of new drug development: is it really $802 million? Health Affairs. 2006;25(2):420–428; Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2018;20(2):273–286; Thomas DW, Burns J, Audette J, Carroll A, Dow-Hygelund C, Hay M. Clinical Development Success Rates 2006–2015. Biotechnology Innovation Organization. June 2016. www.bio.org/sites/default/files/Clinical%20Development%20Success%20Rates%202006-2015%20-%20BIO,%20Biomedtracker,%20Amplion%202016.pdf. Accessed June 28, 2019.
75. Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA. 2016;316(8):858–871; Gaffney A, Lexchin J. Healing an ailing pharmaceutical system: prescription for reform for United States and Canada. BMJ. 2018;361:k1039.
76. Bunis D. Medicare “doughnut hole” will close in 2019. AARP. February 9, 2018. www.aarp.org/health/medicare-insurance/info-2018/part-d-donut-hole-closes-fd.html. Accessed March 29, 2019.
77. Pasternack A. This pioneering $475,000 cancer drug comes with a money-back guarantee. Fast Company. August 31, 2017. www.fastcompany.com/40461214/how-novartis-is-defending-the-record-475000-price-of-its-pioneering-gene-therapy-cancer-drug-car-t-kymriah. Accessed March 29, 2019.
78. Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA. 2016;316(8):858–871.
79. Herper M. Solving the drug patent problem. Forbes. May 2, 2002. www.forbes.com/2002/05/02/0502patents.html#3199af4317bc. Accessed June 28, 2019; Fox E. How pharma companies game the system to keep drugs expensive. Harvard Business Review. April 6, 2017. https://hbr.org/2017/04/how-pharma-companies-game-the-system-to-keep-drugs-expensive. Accessed June 28, 2019.
80. Table 1, cost comparison table for drugs in early and advanced idiopathic Parkinson disease. In: Rotigotine (Neupro) (Transdermal Patch) [Internet]. Canadian Agency for Drugs and Technologies in Health; 2016; Carbidopa/Levodopa. GoodRx. www.goodrx.com/carbidopa-levodopa. Accessed March 29, 2019.
81. Atlas: Country Resources for Neurological Disorders. World Health Organization; 2004.
82. WHO Model List of Essential Medicines. World Health Organization; April 2015.
83. Branswell H. Health officials set to release a list of drugs everyone on earth should be able to access. STAT. June 5, 2017. www.statnews.com/2017/06/05/essential-medicines-list-who. Accessed March 28, 2019.
84. Katzenschlager R, Evans A, Manson A, et al. Mucuna pruriens in Parkinson’s disease: a double blind clinical and pharmacological study. Journal of Neurology, Neurosurgery & Psychiatry. 2004;75(12):1672.
85. Ibid.; Cilia R, Laguna J, Cassani E, et al. Mucuna pruriens in Parkinson disease: a double-blind, randomized, controlled, crossover study. Neurology. 2017;89(5):432–438.